b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="phenaturepg" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC2908552/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908552/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="AIDS Research and Therapy" /><meta name="citation_title" content="The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients" /><meta name="citation_authors" content="Rachel Van Duyne, Irene Guendel, Kylene Kehn-Hall, Rebecca Easley, Zachary Klase, Chenglong Liu, Mary Young, Fatah Kashanchi" /><meta name="citation_date" content="2010" /><meta name="citation_volume" content="7" /><meta name="citation_doi" content="10.1186/1742-6405-7-21" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2908552/?report=abstract" /><meta name="citation_pmid" content="20604950" /><meta name="DC.Title" content="The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Nature Publishing Group" /><meta name="DC.Contributor" content="Rachel Van Duyne" /><meta name="DC.Contributor" content="Irene Guendel" /><meta name="DC.Contributor" content="Kylene Kehn-Hall" /><meta name="DC.Contributor" content="Rebecca Easley" /><meta name="DC.Contributor" content="Zachary Klase" /><meta name="DC.Contributor" content="Chenglong Liu" /><meta name="DC.Contributor" content="Mary Young" /><meta name="DC.Contributor" content="Fatah Kashanchi" /><meta name="DC.Date" content="2010" /><meta name="DC.Identifier" content="10.1186/1742-6405-7-21" /><meta name="DC.Language" content="en" /><meta property="og:title" content="The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients" /><meta property="og:type" content="article" /><meta property="og:description" content="The search for disease biomarkers within human peripheral fluids has become a favorable approach to preventative therapeutics throughout the past few years. The comparison of normal versus disease states can identify an overexpression or a suppression ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908552/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-phenaturepg.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2908552/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2908552/pdf/12981_2010_Article_150.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1BDA23E9A475410000000003760376.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=Nature%20Public%20Health%20Emergency%20Collection[filter]" class="navlink">Nature Public Health Emergency Collection</a></li><li class="accid">PMC2908552</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div class="banner-generic-logo-background inline_block"><div class="banner-journal-publisher-over-image"><div class="banner-journal-name bl-jtitle-phenaturepg">AIDS Research and Therapy</div><div class="banner-publisher-name">Nature Publishing Group</div></div></div></div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">AIDS Res Ther</span>. 2010; 7: 21. </span></div><div><span class="fm-vol-iss-date">Published online 2010 Jul 6. </span>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.1186%2F1742-6405-7-21" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1186/1742-6405-7-21</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2908552</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/20604950">20604950</a></div></div></div></div><h1 class="content-title">The identification of unique serum proteins of HIV-1 latently infected long-term non-progressor patients</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Van%20Duyne%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950" class="affpopup" co-rid="_co_idm140151276101264" co-class="co-affbox">Rachel Van Duyne</a>,<sup>1,</sup><sup>2</sup> <a href="/pubmed/?term=Guendel%20I%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950" class="affpopup" co-rid="_co_idm140151279752432" co-class="co-affbox">Irene Guendel</a>,<sup>2</sup> <a href="/pubmed/?term=Kehn-Hall%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950" class="affpopup" co-rid="_co_idm140151266536000" co-class="co-affbox">Kylene Kehn-Hall</a>,<sup>2</sup> <a href="/pubmed/?term=Easley%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950" class="affpopup" co-rid="_co_idm140151266566160" co-class="co-affbox">Rebecca Easley</a>,<sup>2</sup> <a href="/pubmed/?term=Klase%20Z%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950" class="affpopup" co-rid="_co_idm140151266563904" co-class="co-affbox">Zachary Klase</a>,<sup>3</sup> <a href="/pubmed/?term=Liu%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950" class="affpopup" co-rid="_co_idm140151271817520" co-class="co-affbox">Chenglong Liu</a>,<sup>4</sup> <a href="/pubmed/?term=Young%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950" class="affpopup" co-rid="_co_idm140151274951392" co-class="co-affbox">Mary Young</a>,<sup>4</sup> and  <a href="/pubmed/?term=Kashanchi%20F%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950" class="affpopup" co-rid="_co_idm140151277036000" co-class="co-affbox">Fatah Kashanchi</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>2,</sup><sup>5</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm140151276101264"><h3 class="no_margin">Rachel Van Duyne</h3><p><sup>1</sup>The George Washington University Medical Center, Department of Microbiology, Immunology, and Tropical Medicine, Washington, DC 20037 USA </p><p><sup>2</sup>George Mason University, Department of Molecular and Microbiology, National Center for Biodefense &#x00026; Infectious Diseases, Manassas, VA 20110 USA </p><div>Find articles by <a href="/pubmed/?term=Van%20Duyne%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950">Rachel Van Duyne</a></div></div><div id="_co_idm140151279752432"><h3 class="no_margin">Irene Guendel</h3><p><sup>2</sup>George Mason University, Department of Molecular and Microbiology, National Center for Biodefense &#x00026; Infectious Diseases, Manassas, VA 20110 USA </p><div>Find articles by <a href="/pubmed/?term=Guendel%20I%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950">Irene Guendel</a></div></div><div id="_co_idm140151266536000"><h3 class="no_margin">Kylene Kehn-Hall</h3><p><sup>2</sup>George Mason University, Department of Molecular and Microbiology, National Center for Biodefense &#x00026; Infectious Diseases, Manassas, VA 20110 USA </p><div>Find articles by <a href="/pubmed/?term=Kehn-Hall%20K%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950">Kylene Kehn-Hall</a></div></div><div id="_co_idm140151266566160"><h3 class="no_margin">Rebecca Easley</h3><p><sup>2</sup>George Mason University, Department of Molecular and Microbiology, National Center for Biodefense &#x00026; Infectious Diseases, Manassas, VA 20110 USA </p><div>Find articles by <a href="/pubmed/?term=Easley%20R%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950">Rebecca Easley</a></div></div><div id="_co_idm140151266563904"><h3 class="no_margin">Zachary Klase</h3><p><sup>3</sup>Molecular Virology Section, Laboratory of Molecular Microbiology, NIAID, National Institutes of Health, Bethesda, Maryland 20892-0460 USA </p><div>Find articles by <a href="/pubmed/?term=Klase%20Z%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950">Zachary Klase</a></div></div><div id="_co_idm140151271817520"><h3 class="no_margin">Chenglong Liu</h3><p><sup>4</sup>Washington Metropolitan Women\'s Interagency HIV Study, Division of Infectious Diseases, Georgetown University Medical Center, Washington, DC 20007 USA </p><div>Find articles by <a href="/pubmed/?term=Liu%20C%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950">Chenglong Liu</a></div></div><div id="_co_idm140151274951392"><h3 class="no_margin">Mary Young</h3><p><sup>4</sup>Washington Metropolitan Women\'s Interagency HIV Study, Division of Infectious Diseases, Georgetown University Medical Center, Washington, DC 20007 USA </p><div>Find articles by <a href="/pubmed/?term=Young%20M%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950">Mary Young</a></div></div><div id="_co_idm140151277036000"><h3 class="no_margin">Fatah Kashanchi</h3><p><sup>2</sup>George Mason University, Department of Molecular and Microbiology, National Center for Biodefense &#x00026; Infectious Diseases, Manassas, VA 20110 USA </p><p><sup>5</sup>National Center for Biodefense and Infectious Diseases Professor of Microbiology George Mason University Discovery Hall, Room 306 10900 University Blvd. MS 1H8, Manassas, VA 20110 USA </p><div>Find articles by <a href="/pubmed/?term=Kashanchi%20F%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20604950">Fatah Kashanchi</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm140151272537792_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm140151272537792_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm140151272537792_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm140151272537792_ai" style="display:none"><div class="fm-affl" lang="en" id="Aff1"><sup>1</sup>The George Washington University Medical Center, Department of Microbiology, Immunology, and Tropical Medicine, Washington, DC 20037 USA </div><div class="fm-affl" lang="en" id="Aff2"><sup>2</sup>George Mason University, Department of Molecular and Microbiology, National Center for Biodefense &#x00026; Infectious Diseases, Manassas, VA 20110 USA </div><div class="fm-affl" lang="en" id="Aff3"><sup>3</sup>Molecular Virology Section, Laboratory of Molecular Microbiology, NIAID, National Institutes of Health, Bethesda, Maryland 20892-0460 USA </div><div class="fm-affl" lang="en" id="Aff4"><sup>4</sup>Washington Metropolitan Women\'s Interagency HIV Study, Division of Infectious Diseases, Georgetown University Medical Center, Washington, DC 20007 USA </div><div class="fm-affl" lang="en" id="Aff5"><sup>5</sup>National Center for Biodefense and Infectious Diseases Professor of Microbiology George Mason University Discovery Hall, Room 306 10900 University Blvd. MS 1H8, Manassas, VA 20110 USA </div><div><span class="fm-affl">Rachel Van Duyne, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmuwg@vvrmcb" class="oemail">ude.cmuwg@vvrmcb</a></span>.</div><div><a href="#idm140151272537792aff-info">Contributor Information</a>.</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm140151272537792_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2010 Mar 15; Accepted 2010 Jul 6.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm140151272537792_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; Van Duyne et al; licensee BioMed Central Ltd. 2010</div><div class="license half_rhythm">This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC2908552/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="Abs1" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="Abs1title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3 id="__sec1title">Background</h3><p id="__p1" class="p p-first-last">The search for disease biomarkers within human peripheral fluids has become a favorable approach to preventative therapeutics throughout the past few years. The comparison of normal versus disease states can identify an overexpression or a suppression of critical proteins where illness has directly altered a patient\'s cellular homeostasis. In particular, the analysis of HIV-1 infected serum is an attractive medium with which to identify altered protein expression due to the ease and non-invasive methods of collecting samples as well as the corresponding insight into the <em>in vivo</em> interaction of the virus with infected cells/tissue. The utilization of proteomic techniques to globally identify differentially expressed serum proteins in response to HIV-1 infection is a significant undertaking that is complicated due to the innate protein profile of human serum.</p></div><div id="__sec2" class="sec"><h3 id="__sec2title">Results</h3><p id="__p2" class="p p-first-last">Here, the depletion of 12 of the most abundant serum proteins, followed by two-dimensional gel electrophoresis coupled with identification of these proteins using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, has allowed for the identification of differentially expressed, low abundant serum proteins. We have analyzed and compared serum samples from HIV-1 infected subjects who are being treated using highly active antiretroviral therapy (HAART) to those who are latently infected but have not progressed to AIDS despite the absence of treatment, i.e. long term non-progressors (LTNPs). Here we have identified unique serum proteins that are differentially expressed in LTNP HIV-1 patients and may contribute to the ability of these patients to combat HIV-1 infection in the absence of HAART. We focused on the cdk4/6 cell cycle inhibitor p16<sup>INK4A</sup> and found that the treatment of HIV-1 latently infected cell lines with p16<sup>INK4A</sup> decreases viral production despite it not being expressed endogenously in these cells.</p></div><div id="__sec3" class="sec"><h3 id="__sec3title">Conclusions</h3><p id="__p3" class="p p-first-last">Identification of these unique proteins may serve as an indication of altered viral states in response to infection as well as a natural phenotypic variability in response to HIV-1 infection in a given population.</p></div><div id="__sec4" class="sec sec-last"><h3 id="__sec4title">Electronic supplementary material</h3><p id="__p4" class="p p-first-last">The online version of this article (doi:10.1186/1742-6405-7-21) contains supplementary material, which is available to authorized users.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">Jurkat Cell, Cellular Viability, Reverse Transcriptase Activity, Abundance Fraction, Serum Proteome</span></div></div><div id="Sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec1title">Background</h2><p id="__p5" class="p p-first">Human serum is derived from the liquid plasma component of the blood with the fibrinogens, or clotting factors, removed and is composed of small molecules such as salts, lipids, amino acids, sugars and approximately 60-80 mg of proteins/mL [<a href="#CR1" rid="CR1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364091">1</a>]. Serum is a readily obtainable peripheral bodily fluid from which the protein profile directly reflects the normal or disease state of the organism [<a href="#CR2" rid="CR2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364093">2</a>&#x02013;<a href="#CR4" rid="CR4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364122">4</a>]. Serum is a complex mixture of "classical" and "non-classical" proteins. Classical serum proteins are involved in a number of processes including proteolysis, inhibition, binding, transport, coagulation, and immune response and are often secreted from the liver, through the intestines, and into the bloodstream [<a href="#CR5" rid="CR5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364086">5</a>]. "Non-classical" proteins are proteins that are not directly tied to any known function within the serum and often originate from cellular leakage or shedding, and may utilize the bloodstream for transportation [<a href="#CR5" rid="CR5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364117">5</a>]. It is generally accepted that most of the significant changes in the serum will be found in these low abundant non-classical proteins, due to the hypothesis that the presence of these proteins should reflect changes in the diseased tissue. Indeed, serum commonly contains upwards of 10,000 different proteins at any given time that are being actively produced and secreted by all cells and tissues, therefore, the proteomic profile of serum can give insight into the systemic reaction to a disease state and can serve as a pool of differentially expressed proteins [<a href="#CR2" rid="CR2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364109">2</a>, <a href="#CR6" rid="CR6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364119">6</a>&#x02013;<a href="#CR13" rid="CR13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364112">13</a>]. Recently, the interest in characterizing the human serum proteome has increased due to the determination of disease biomarkers for early detection, diagnosis, and drug targeting; however, due to the extensive dynamic range of protein concentration within the serum, the identification of low abundance proteins suitable for biomarker determination is often masked. The 22 highly abundant proteins contained within serum constitute approximately 99% of the total serum proteins, including albumin, IgG, transferrin, haptoglobin, fibrinogen, etc. and interfere with the identification of low abundance proteins in the ng/mL concentration range. The presence of these highly abundant proteins necessitates the prefractionation of serum samples prior to analysis for low abundant proteins. Due to the dynamic insight the analysis of the serum proteome can relate to a disease state, of particular interest is the identification of low abundant proteins that change in expression or abundance in response to a disease state. These low abundant proteins could potentially arise as an early diagnostic for a disease state, or a therapeutic target.</p><p id="__p6">Serum proteomics has emerged as an integral biomarker identification and diagnostic tool, especially for infectious diseases and oncology. Recently, novel serum biomarkers have been identified for liver fibrosis in hepatitis C virus (HCV) infected patients as well as unique protein signatures in SARS coronavirus infections, and infant hepatitis syndrome induced by human cytomegalovirus (HCMV) infection [<a href="#CR14" rid="CR14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364084">14</a>&#x02013;<a href="#CR16" rid="CR16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364113">16</a>]. Characterization of the serum protein profile of these viral states helps provide insight into the expression changes associated with viral infection. In particular, HIV-1 infection, even at the acute phase, results in dramatic changes in both cellular and viral protein expression levels. As the HIV-1 viral tropism consists primarily of CD4+ T-cells, macrophages, and dendritic cells, the resulting protein changes can be seen systemically as infected cells travel throughout the body. Additionally, the nature of this viral infection supports the secretion of altered proteins into the blood and subsequently the serum due to the propensity of the virus to stimulate apoptosis of infected cells, therefore emptying cellular contents into the serum. These characteristics of HIV-1 infection suggest that the analysis of the serum of infected patients is an appropriate reflection of a patients\' altered protein expression state.</p><p id="__p7">Due to innate genetic and phenotypic differences in the human population, significant variability exists in the susceptibility to HIV-1 infection. Amongst this diversity includes the well-studied CCR5&#x00394;32 inherited mutation, which prevents the binding of R5-tropic HIV-1 strains to the CCR5 chemokine receptor on the surface of CD4+ T-cells, therefore preventing entry of the virus [<a href="#CR17" rid="CR17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364085">17</a>]. Additionally, some individuals can be infected with HIV-1, however will not progress to AIDS even in the absence of therapy. These Long Term Non-Progressors (LTNPs) are often characterized as being infected with HIV-1 but are also disease free and sustain a normal CD4 T-cell count and a low viral load. Over the past 20 years, multiple studies have been aimed at determining the reason that these individuals are able to resist disease progression. There are studies that suggest that the virus infecting these cells could be deficient in some way, for example, Nef deficient viruses and Vpr R77Q mutations are associated with LTNPs [<a href="#CR18" rid="CR18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364082">18</a>&#x02013;<a href="#CR22" rid="CR22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364100">22</a>]. A number of host factors have also been identified that may contribute to the observed resistance. LTNPs have a higher prevalence of the CCR5&#x00394;32 allele [<a href="#CR17" rid="CR17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364090">17</a>, <a href="#CR23" rid="CR23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364118">23</a>&#x02013;<a href="#CR25" rid="CR25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364110">25</a>]. In addition, the presence of certain HLA genes including HLA-B27, HLA-B*5701, HLA-B*5401, and HLA-B*1507 have been linked to LTNP [<a href="#CR26" rid="CR26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364116">26</a>&#x02013;<a href="#CR28" rid="CR28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364092">28</a>] however, the identified alterations do not account for all cases of LTNP. Therefore, the search for protective host factors is still an area of active investigation in hopes of obtaining information that could be of therapeutic value.</p><p id="__p8" class="p p-last">Here, we describe the detection of unique, low abundant serum proteins in latently infected HIV-1 LTNPs as compared to serum from patients undergoing HAART treatment, and those not infected with HIV-1. We attempted to characterize the underlying differences in LTNPs that contribute to the ability of these patients to combat HIV-1 infections. We have depleted 12 of the most highly abundant serum proteins from three sets of serum samples (uninfected, infected on HAART, LTNP) and identified differentially expressed proteins across the samples. In particular, we focus on the identified cellular protein p16<sup>INK4A</sup> which is found preferentially in LTNP patient serum samples, but is not present in patients undergoing HAART treatment. <em>In vitro</em> viral assays and viability studies confirm the loss of viral replication upon p16<sup>INK4A</sup> treatment in latently infected cell lines and the non-toxic effect of the same treatment in corresponding uninfected cell lines.</p></div><div id="Sec2" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec2title">Results</h2><div id="Sec3" class="sec sec-first"><h3 id="Sec3title">Depletion of the 12 highly abundant serum proteins allows for the identification of low abundant proteins</h3><p id="__p9" class="p p-first-last">To begin the identification of unique serum proteins, we obtained 18 subject serum samples: six LTNP, six HIV-1 infected subjects receiving HAART therapy (HAART) and six HIV-uninfected individuals through the Washington DC site of the Women\'s Interagency HIV Study (WIHS) Georgetown site (Table <a href="/pmc/articles/PMC2908552/table/Tab1/" target="table" class="fig-table-link figpopup" rid-figpopup="Tab1" rid-ob="ob-Tab1" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">(Table1).</span></span><span>1</span></a>). WIHS is an NIH multicenter study of the natural history of HIV-1 infection in women [<a href="#CR29" rid="CR29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364077">29</a>]. LTNPs are defined by WIHS as being HIV-1 infected, but disease free for at least five years, having a CD4 count of greater than 500 at all visits and having no history of anti-retroviral therapy. The difficulty associated with analyzing serum is the presence of a high abundance of proteins which mask potential low abundance biomarkers. To overcome this obstacle, we utilized the ProteomeLab IgY serum depletion kit which removes 12 of the most abundant proteins in serum: albumin, IgG, transferrin, fibrinogen, IgA, &#x003b1;2-macroglobulin, IgM, &#x003b1;1-antitrypsin, haptoglobin, &#x003b1;1-acid glycoprotein, apolipoprotein A-I, and apolipoprotein A-II. As can be observed in Figure <a href="/pmc/articles/PMC2908552/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure1A,</span></span><span>1A</span></a>, whole serum (lanes 2, 3) contains many proteins and is too complex to allow for confident identification of specific proteins. However, when the high abundant proteins (Figure <a href="/pmc/articles/PMC2908552/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure1,</span></span><span>1</span></a>, lanes 8, 9) are removed, lower abundant proteins that were originally masked (Figure <a href="/pmc/articles/PMC2908552/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure1,</span></span><span>1</span></a>, lanes 4, 5) are able to be analyzed. Along these lines, we found the ProteomeLab IgY serum depletion kit to be the most appropriate and reproducible manner in which to fractionate our serum samples into high and low abundant fractions. We applied this depletion strategy to pooled patient samples, combining equal volumes of whole serum from each of the six patients per sample set (LTNP, HAART, and Negative), which were subsequently depleted into low and high abundance fractions. We began the analysis with pooled samples to assist in the identification of HIV-1 infection specific protein identification as opposed to identifying individual patient and serum variability. These pooled samples were separated based on 1D SDS-PAGE (Figure <a href="/pmc/articles/PMC2908552/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure1B)</span></span><span>1B</span></a>) and comparisons between LTNP, HAART, and Negative low abundant samples were carried out via in-gel trypsin digestion, peptide elution and desalting, followed by MALDI-TOF mass spectrometry as indicated by numbered arrows marking excised bands. The subsequent protein identifications served as a preliminary indication of differentially expressed proteins between the three patient types. These observations, as summarized in Table <a href="/pmc/articles/PMC2908552/table/Tab2/" target="table" class="fig-table-link figpopup" rid-figpopup="Tab2" rid-ob="ob-Tab2" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">Table2,</span></span><span>2</span></a>, provide an insight into the relevance of proteins identified in the context of the state of HIV-1 infection. Of particular interest in Table <a href="/pmc/articles/PMC2908552/table/Tab2/" target="table" class="fig-table-link figpopup" rid-figpopup="Tab2" rid-ob="ob-Tab2" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">Table2</span></span><span>2</span></a> is the identification of HIV-1 enhancer binding protein 1, (HIVEP1), Ribonuclease III, and heterochromatin protein 1 binding protein in the low abundance LTNP fraction. HIVEP1 is a member of the ZAS family of proteins which bind the promoter and enhancer regions of both cellular genes and infectious viruses, including HIV-1. Also known as PRDII-BF1 or MBP-1, this transcription factor binds to both the NF-&#x003ba;B and the TAR transactivation response DNA elements on the HIV-1 LTR in both the presence and absence of HIV-1 Tat [<a href="#CR30" rid="CR30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364120">30</a>, <a href="#CR31" rid="CR31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364101">31</a>]. It is not surprising that a transcription factor such as HIVEP1 would be present during HIV-1 infection; however, the identification of this protein is not necessarily a marker for a LTNP phenotype. Ribonuclease III, or Drosha, is a cellular enzyme found in the nucleus which serves to cleave double-stranded RNA hairpin transcripts as a key step in the production of miRNAs in the RNA interference pathway. Interestingly, heterochromatin protein 1, or HP1 is a member of the chromatin remodeling family of proteins, which can bind histones at methylated lysine residues and can interact with many chromatin-associated nonhistone proteins. The HP1 family of proteins has been associated with promoting a heterochromatic cellular state, where latently HIV-1 infected cells can persist as a transcriptionally silent provirus [<a href="#CR32" rid="CR32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364097">32</a>, <a href="#CR33" rid="CR33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364096">33</a>]. It may be of interest that an HP1 binding protein would be present in the serum of an HIV-1 infected patient as HP1, including its subtypes &#x003b1;, &#x003b2;, and &#x003b3;, could be involved in the control of various stages of infection. It is possible that the association of this HP1 binding protein with varying subtype of HP1 could explain the differences in patient phenotypes, especially those that result in an altered susceptibility to viral infection.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="Tab1"><h3>Table 1</h3><!--caption a7--><div class="caption"><p id="__p10">Patient samples obtained from the WIHS Interagency Cohort.</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140151283040224" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="center" rowspan="1" colspan="1">Ref. #</th><th align="center" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Concentration (&#x003bc;g/&#x003bc;l)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">\n<strong>1</strong>\n</td><td align="center" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">11.26</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>2</strong>\n</td><td align="center" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">10.80</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>3</strong>\n</td><td align="center" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">11.85</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>4</strong>\n</td><td align="center" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">11.44</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>5</strong>\n</td><td align="center" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">12.05</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>6</strong>\n</td><td align="center" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">12.12</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>7</strong>\n</td><td align="center" rowspan="1" colspan="1">HAART Responder</td><td align="center" rowspan="1" colspan="1">12.18</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>8</strong>\n</td><td align="center" rowspan="1" colspan="1">HAART Responder</td><td align="center" rowspan="1" colspan="1">12.80</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>9</strong>\n</td><td align="center" rowspan="1" colspan="1">HAART Responder</td><td align="center" rowspan="1" colspan="1">12.23</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>10</strong>\n</td><td align="center" rowspan="1" colspan="1">HAART Responder</td><td align="center" rowspan="1" colspan="1">12.12</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>11</strong>\n</td><td align="center" rowspan="1" colspan="1">HAART Responder</td><td align="center" rowspan="1" colspan="1">11.04</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>12</strong>\n</td><td align="center" rowspan="1" colspan="1">HAART Responder</td><td align="center" rowspan="1" colspan="1">11.79</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>13</strong>\n</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">10.43</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>14</strong>\n</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">11.97</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>15</strong>\n</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">12.55</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>16</strong>\n</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">12.83</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>17</strong>\n</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">12.32</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>18</strong>\n</td><td align="center" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">11.60</td></tr></tbody></table></div><div id="largeobj_idm140151283040224" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2908552/table/Tab1/?report=objectonly">Open in a separate window</a></div></div><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="Tab2"><h3>Table 2</h3><!--caption a7--><div class="caption"><p id="__p11">Protein Identification of Serum Depleted Samples from 1D SDS-PAGE</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140151266950176" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="center" rowspan="1" colspan="1">Spot #</th><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Type</th><th align="left" rowspan="1" colspan="1">Protein Name</th><th align="left" rowspan="1" colspan="1">Accession #</th><th align="center" rowspan="1" colspan="1">pI</th><th align="center" rowspan="1" colspan="1">MW (kDa)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">\n<strong>2</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Human immunodeficiency virus type 1 enhancer binding protein 1</td><td align="left" rowspan="1" colspan="1">gi 55662194</td><td align="center" rowspan="1" colspan="1">8.3</td><td align="center" rowspan="1" colspan="1">296.68</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>3</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Ribonuclease III (Drosha)</td><td align="left" rowspan="1" colspan="1">gi 20139357</td><td align="center" rowspan="1" colspan="1">8.5</td><td align="center" rowspan="1" colspan="1">159.23</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>4</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">ADAM metallopeptidase with thrombospondin type 1 motif, 18</td><td align="left" rowspan="1" colspan="1">gi 38649249</td><td align="center" rowspan="1" colspan="1">9.7</td><td align="center" rowspan="1" colspan="1">135.12</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>5</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Tax1-binding protein TXBP151</td><td align="left" rowspan="1" colspan="1">gi 5776545</td><td align="center" rowspan="1" colspan="1">5.3</td><td align="center" rowspan="1" colspan="1">86.23</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>7</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Heterochromatin protein 1, binding protein</td><td align="left" rowspan="1" colspan="1">gi 55961949</td><td align="center" rowspan="1" colspan="1">9.8</td><td align="center" rowspan="1" colspan="1">57.19</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>8</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Gga-Vhs domain &#x00026; Beta-Secretase C-terminal phosphopeptide</td><td align="left" rowspan="1" colspan="1">gi 38492866</td><td align="center" rowspan="1" colspan="1">5.5</td><td align="center" rowspan="1" colspan="1">17.92</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>11</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">MHC class I antigen</td><td align="left" rowspan="1" colspan="1">gi 33413287</td><td align="center" rowspan="1" colspan="1">8.0</td><td align="center" rowspan="1" colspan="1">10.43</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>1</strong>\n</td><td align="left" rowspan="1" colspan="1">HAART</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Coagulation factor V (Proaccelerin, labile factor)</td><td align="left" rowspan="1" colspan="1">gi 56417672</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">252.19</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>6</strong>\n</td><td align="left" rowspan="1" colspan="1">Uninfected</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Matrix metalloproteinase 2 preprotein</td><td align="left" rowspan="1" colspan="1">gi 11342666</td><td align="center" rowspan="1" colspan="1">5.3</td><td align="center" rowspan="1" colspan="1">73.86</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>9</strong>\n</td><td align="left" rowspan="1" colspan="1">Uninfected</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Ribosomal protein L27</td><td align="left" rowspan="1" colspan="1">gi 4506623</td><td align="center" rowspan="1" colspan="1">10.6</td><td align="center" rowspan="1" colspan="1">15.78</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>10</strong>\n</td><td align="left" rowspan="1" colspan="1">Uninfected</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Ribosomal protein L36a</td><td align="left" rowspan="1" colspan="1">gi 10445223</td><td align="center" rowspan="1" colspan="1">11.1</td><td align="center" rowspan="1" colspan="1">12.42</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>12</strong>\n</td><td align="left" rowspan="1" colspan="1">Uninfected</td><td align="center" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">P63 protein</td><td align="left" rowspan="1" colspan="1">gi 34304700</td><td align="center" rowspan="1" colspan="1">7.1</td><td align="center" rowspan="1" colspan="1">11.39</td></tr></tbody></table></div><div id="largeobj_idm140151266950176" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2908552/table/Tab2/?report=objectonly">Open in a separate window</a></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig1" co-legend-rid="lgnd_Fig1"><a href="/pmc/articles/PMC2908552/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140151272560320" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12981_2010_Article_150_Fig1_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12981_2010_Article_150_Fig1_HTML.jpg" src="/pmc/articles/PMC2908552/bin/12981_2010_Article_150_Fig1_HTML.jpg" /></div><div id="largeobj_idm140151272560320" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2908552/figure/Fig1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig1"><div><a class="figpopup" href="/pmc/articles/PMC2908552/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="__p12"><strong>1D Demonstration of the depletion capabilities of the IgY-12 High Capacity SC Spin Column kit on patient serum</strong>. Depletion of patient serum was performed as indicated by manufacturer\'s instructions. Low and High abundant fractions were collected for each sample and run on a 1D 4-20% Tris-Gycine SDS-PAGE gel. <strong>A)</strong> Whole serum (lanes 2, 3) was incubated with the column containing antibodies against 12 of the high abundant serum proteins. Low abundant proteins (lanes 4, 5) were collected as the flowthrough, the column was washed (lanes 6, 7) and the high abundant proteins eluted (lanes 8, 9). Briefly the observed high abundant proteins were compared to the known sizes of the expected proteins as indicated. <strong>B)</strong> Equal volumes of serum from each of the six patients within each category (LTNP, HAART, and Negative) were pooled together to create a stock of each condition, independent of patient-to-patient variability. Twenty microliters of each stock was subjected to depletion and equal concentration of Low and High fraction were run on a 1D gel. Lanes 2, 3 and 4 are the low abundance fractions of the pooled LTNP, HAART, and Negative patients, respectively. Lanes 6, 8, and 10 are the high abundance fractions of the pooled LTNP, HAART, and Negative patients, respectively. The indicated arrows represent differentially expressed proteins that were excised, trypsinized, and identified using MALDI-TOF for preliminary protein screening.</p></div></div></div></div><div id="Sec4" class="sec"><h3 id="Sec4title">2DGE and MALDI-TOF analysis of pooled, depleted serum samples identified unique low abundance proteins</h3><p id="__p13" class="p p-first">Following the initial 1D separation and MALDI-TOF MS assisted identification, the pooled patient samples were subjected to 2D-gel electrophoresis (2DGE); isoelectric focusing (IEF) using IPG strips with a pH 3.0-10.0 range followed by SDS-PAGE using 4-20% Tris-Glycine Criterion gels. The method of 2D-gel electrophoresis is much more sensitive than 1D-gel electrophoresis in that it provides separation of a complex mixture of proteins in two dimensions, therefore removing the complexity associated with overlapping proteins, or masking due to post-translational modifications. 2DGE is a more sensitive front-end purification approach to the isolation and identification of individual protein species by mass spectrometry. Figure <a href="/pmc/articles/PMC2908552/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure2</span></span><span>2</span></a> depicts the LTNP, HAART, and Negative low abundance fractions in gels "a", "b", and "c", respectively, as well as the LTNP, HAART, and Negative high abundance fractions in gels "d", "e", and "f", respectively. Indicated protein spots from all gels were excised based on a comparison of protein abundance and the presence of unique spots in a given patient set, were subjected to in-gel trypsin digestion, and were identified by MALDI-TOF mass spectrometry. It is important to note that although gels "d," "e," and "f" contain the majority of the high abundance proteins, unique small protein spots can still be visualized on these gels. This indicates that not only will these high abundant proteins mask proteins of interest; they can also interact with and seclude lower abundance proteins from being identified. Peak lists from the collected mass spectra were processed via peptide mass fingerprinting (PMF) analysis using the Mascot and ProFound databases, compared, and compiled into a non-exhaustive list of identified proteins as displayed in Table <a href="/pmc/articles/PMC2908552/table/Tab3/" target="table" class="fig-table-link figpopup" rid-figpopup="Tab3" rid-ob="ob-Tab3" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -2.5em;">Table3.</span></span><span>3</span></a>. Of particular interest are those proteins identified from gel "a" indicating unique low abundance proteins in the serum of LTNP patients: Tropomyosin 3, protein kinase 3, and cdk4/6 binding protein p16. Tropomyosin interacts with actin filaments to provide stability and regulates other actin binding proteins. This family of proteins has been shown to be cleaved by HIV-1 protease <em>in vitro</em>, resulting in the dissociation of critical cytoskeletal elements, which may demonstrate the alteration of muscle structure in the presence of an HIV-1 infection [<a href="#CR34" rid="CR34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364099">34</a>]. Protein kinase 3, or Protein kinase C (PKC) is a member of the family of serine/threonine kinases that are integrally involved in key cellular signaling pathways and can phosphorylate a wide variety of substrates. Not surprisingly, HIV-1 infection alters the PKC phosphorylation pathway to stimulate TNF-&#x003b1; production by monocytes as well as other cytokines and growth factors such as IL-6, IL-10, and MCP-1 [<a href="#CR35" rid="CR35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364114">35</a>&#x02013;<a href="#CR39" rid="CR39" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364115">39</a>]. PKC has also been shown to be necessary for HIV-1 Tat-mediated transactivation as well as directly phosphorylating Tat at serine 46 [<a href="#CR40" rid="CR40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364075">40</a>, <a href="#CR41" rid="CR41" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364083">41</a>] and plays an integral role in the signaling and secretion of cytokines in response to HIV-1 envelope proteins gp120, gp160, and gp41 [<a href="#CR42" rid="CR42" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364104">42</a>, <a href="#CR43" rid="CR43" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364079">43</a>]. Of particular interest in the low abundance, LTNP fraction is the presence of the cdk4/cdk6 binding protein p16, or more specifically, p16<sup>INK4A</sup>, a member of the inhibitor of kinase 4/alternative reading frame (INK4/ARF) family of endogenous cdk (cyclin-dependent kinase) inhibitors [<a href="#CR44" rid="CR44" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364107">44</a>]. Dysregulation of the cell cycle, including the manipulation of cdks and their associated Cyclins is often a hallmark of cancerous and infectious phenotypes. Indeed HIV-1 and its associated proteins have been known to alter the phosphorylation state and activity of these kinases. P16<sup>INK4A</sup> inhibits the phosphorylation of Rb by competitively inhibiting the association of cdk4/Cyclin D therefore inhibiting the release of Rb-bound proteins, such as E2F, and the subsequent progression into the S phase of the cell cycle [<a href="#CR44" rid="CR44" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364095">44</a>, <a href="#CR45" rid="CR45" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364121">45</a>]. This small molecular weight protein is an attractive candidate for a secreted, differentially expressed protein in response to HIV-1 infection.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="Tab3"><h3>Table 3</h3><!--caption a7--><div class="caption"><p id="__p14">Protein Identification of Serum Depleted Samples from 2D SDS-PAGE</p></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140151268143136" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="left" rowspan="1" colspan="1">Spot #</th><th align="left" rowspan="1" colspan="1">Group</th><th align="center" rowspan="1" colspan="1">Type</th><th align="left" rowspan="1" colspan="1">Protein Name</th><th align="left" rowspan="1" colspan="1">Accession #</th><th align="left" rowspan="1" colspan="1">pI</th><th align="center" rowspan="1" colspan="1">MW (kDa)</th><th align="center" rowspan="1" colspan="1">% Coverage</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">\n<strong>A2</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Serum albumin</td><td align="left" rowspan="1" colspan="1">gi 23307793</td><td align="left" rowspan="1" colspan="1">6.1</td><td align="center" rowspan="1" colspan="1">69.38</td><td align="center" rowspan="1" colspan="1">14%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>A4</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Tropomyosin 3</td><td align="left" rowspan="1" colspan="1">gi 55665778</td><td align="left" rowspan="1" colspan="1">4.8</td><td align="center" rowspan="1" colspan="1">26.26</td><td align="center" rowspan="1" colspan="1">13%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>A6</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Protein kinase 3</td><td align="left" rowspan="1" colspan="1">gi 4226043</td><td align="left" rowspan="1" colspan="1">6.4</td><td align="center" rowspan="1" colspan="1">13.48</td><td align="center" rowspan="1" colspan="1">12%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>A7</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Cyclin D-dependent kinase 4 and 6-binding protein/p16</td><td align="left" rowspan="1" colspan="1">gi 861472</td><td align="left" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">16.51</td><td align="center" rowspan="1" colspan="1">24%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>B1</strong>\n</td><td align="left" rowspan="1" colspan="1">HAART</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Serine/Threonine kinase 33</td><td align="left" rowspan="1" colspan="1">gi 23943882</td><td align="left" rowspan="1" colspan="1">6.6</td><td align="center" rowspan="1" colspan="1">57.81</td><td align="center" rowspan="1" colspan="1">14%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>B3</strong>\n</td><td align="left" rowspan="1" colspan="1">HAART</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Kelch repeat domain containing protein 11</td><td align="left" rowspan="1" colspan="1">gi 7662260</td><td align="left" rowspan="1" colspan="1">5.8</td><td align="center" rowspan="1" colspan="1">65.7</td><td align="center" rowspan="1" colspan="1">12%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>B15</strong>\n</td><td align="left" rowspan="1" colspan="1">HAART</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">SNW1 protein/APAF1 interacting protein</td><td align="left" rowspan="1" colspan="1">gi 40850966</td><td align="left" rowspan="1" colspan="1">9.9</td><td align="center" rowspan="1" colspan="1">35.97</td><td align="center" rowspan="1" colspan="1">21%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>C2</strong>\n</td><td align="left" rowspan="1" colspan="1">Uninfected</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Eukaryotic translation initiation factor 4B</td><td align="left" rowspan="1" colspan="1">gi 49256408</td><td align="left" rowspan="1" colspan="1">5.5</td><td align="center" rowspan="1" colspan="1">69.15</td><td align="center" rowspan="1" colspan="1">10%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>C4</strong>\n</td><td align="left" rowspan="1" colspan="1">Uninfected</td><td align="center" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">RRBP1 protein</td><td align="left" rowspan="1" colspan="1">gi 38014595</td><td align="left" rowspan="1" colspan="1">4.9</td><td align="center" rowspan="1" colspan="1">73.67</td><td align="center" rowspan="1" colspan="1">13%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>D1</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">FGFR1 oncogene partner</td><td align="left" rowspan="1" colspan="1">gi 15080276</td><td align="left" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">40.9</td><td align="center" rowspan="1" colspan="1">12%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>D5</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">Serum albumin</td><td align="left" rowspan="1" colspan="1">gi 23307793</td><td align="left" rowspan="1" colspan="1">6.1</td><td align="center" rowspan="1" colspan="1">69.38</td><td align="center" rowspan="1" colspan="1">15%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>D6</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">Anti-HIV-1 gp120 IgG 16c kappa light chain</td><td align="left" rowspan="1" colspan="1">gi 40647136</td><td align="left" rowspan="1" colspan="1">7.8</td><td align="center" rowspan="1" colspan="1">20.67</td><td align="center" rowspan="1" colspan="1">26%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>D7</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">Serum albumin</td><td align="left" rowspan="1" colspan="1">gi 23307793</td><td align="left" rowspan="1" colspan="1">6.1</td><td align="center" rowspan="1" colspan="1">69.38</td><td align="center" rowspan="1" colspan="1">19%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>D8</strong>\n</td><td align="left" rowspan="1" colspan="1">LTNP</td><td align="center" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">PCTAIRE protein kinase 3</td><td align="left" rowspan="1" colspan="1">gi 55960102</td><td align="left" rowspan="1" colspan="1">9.1</td><td align="center" rowspan="1" colspan="1">54.16</td><td align="center" rowspan="1" colspan="1">18%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>E1</strong>\n</td><td align="left" rowspan="1" colspan="1">HAART</td><td align="center" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">Pre-B-cell leukemia homeobox interacting protein 1</td><td align="left" rowspan="1" colspan="1">gi 55960102</td><td align="left" rowspan="1" colspan="1">5.2</td><td align="center" rowspan="1" colspan="1">72.9</td><td align="center" rowspan="1" colspan="1">9%</td></tr><tr><td align="center" rowspan="1" colspan="1">\n<strong>E2</strong>\n</td><td align="left" rowspan="1" colspan="1">HAART</td><td align="center" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">Serum albumin</td><td align="left" rowspan="1" colspan="1">gi 23307793</td><td align="left" rowspan="1" colspan="1">6.1</td><td align="center" rowspan="1" colspan="1">69.38</td><td align="center" rowspan="1" colspan="1">15%</td></tr></tbody></table></div><div id="largeobj_idm140151268143136" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2908552/table/Tab3/?report=objectonly">Open in a separate window</a></div></div><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig2" co-legend-rid="lgnd_Fig2"><a href="/pmc/articles/PMC2908552/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140151267295872" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12981_2010_Article_150_Fig2_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12981_2010_Article_150_Fig2_HTML.jpg" src="/pmc/articles/PMC2908552/bin/12981_2010_Article_150_Fig2_HTML.jpg" /></div><div id="largeobj_idm140151267295872" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2908552/figure/Fig2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig2"><div><a class="figpopup" href="/pmc/articles/PMC2908552/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="__p15"><strong>Two-dimensional gel electrophoresis of pooled patient samples</strong>. Post sample depletion, six 2D gels (IPG Strip pH 3-10, 4-20% SDS-PAGE) were run in tandem to separate the low and high abundance protein fractions of pooled patient serum samples in tandem. Gels a, b, and c are representative of LTNP, HAART, and Negative low abundance patient samples respectively. Gels d, e, and f are representative of LTNP, HAART, and negative high abundance patient samples respectively. Arrows and circles indicate protein spots excised for MALDI-TOF analysis.</p></div></div></div><p id="__p16">In addition to these low abundant protein identifications, the LTNP high abundant samples (gel "d") indicated the presence of the FGFR1 oncogenic partner and PCTAIRE protein kinase 3 as well as an anti-HIV-1 gp120 IgG 16 c&#x003ba; light chain. FGFR1 oncogene partnered with the fibroblast growth factor receptor 1 (FGFR1) is thought to be associated with myeloproliferative disorders and as of yet is not associated with any HIV-1 protein interactions or associated disease phenotypes. PCTAIRE protein kinase 3, however, is a member of the serine/threonine family of protein kinases and more specifically, the cdc2/cdkx subfamily that plays a role in broad signal transduction pathways. This serine/threonine kinase family member has also been associated with the essential regulation of cell cycle progression, as well as transcription and DNA repair [<a href="#CR46" rid="CR46" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364111">46</a>]. This protein identification again demonstrates the role that HIV-1 infection plays in the dysregulation of cellular kinases and specifically, cell cycle progression.</p><p id="__p17" class="p p-last">The HAART responder patient samples (gels "b" and "e") also contained unique protein candidates: serine/threonine kinase 33, the Kelch repeat domain containing protein 11, and the SNW1 protein/APAF1 interacting protein in the low abundant fraction as well as the pre-B-cell leukemia homeobox interacting protein 1 in the high abundant fraction. Of functional interest is the general serine/threonine kinase 33 as we have already identified several cellular kinases of the same family. Additionally, the SNW1 protein is a transcriptional coactivator that induces the expression of vitamin D, retinoic acid, estrogen, and glucocorticoid associated genes. SNW1/SKIP interacts with HIV-1 Tat through the association with p-TEFb (cdk9/Cyclin T1) at the TAR RNA complex, stimulating HIV-1 transcription elongation [<a href="#CR44" rid="CR44" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364088">44</a>]. Interestingly, some of the protein spots identified the presence of serum albumin contamination (spots a2, d5, d7, and e2), which both served as an internal positive control for mass spectrometry and also indicated that the depletion columns are not completely efficient at removing contaminating high abundant proteins.</p></div><div id="Sec5" class="sec"><h3 id="Sec5title">Validation of MS protein identifications by Western Blot</h3><p id="__p18" class="p p-first">In order to further confirm the presence of these proteins in the serum as identified by mass spectrometry, we performed western blots on the same low and high abundant pooled fractions (Figure <a href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3A).</span></span><span>3A</span></a>). P16<sup>INK4A</sup> is present in both the low and high abundant fractions of the pooled LTNPs (lanes 3, 4) and is also observed in the high abundance fraction of uninfected patients (Figure <a href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3A,</span></span><span>3A</span></a>, lane 2). Interestingly, this protein is not present in HAART patient samples at all (Figure <a href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3A,</span></span><span>3A</span></a>, lane 5, 6). The presence of this protein in serum may be specific to individuals that confer resistance to chronic HIV-1 infection. As p16<sup>INK4A</sup> is an inhibitor of cell cycle kinases, in particular cdk4 and cdk6, the levels of cdk4 in the serum samples was assayed and was shown to be ubiquitously expressed across all low and high abundance serum samples (Figure <a href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3A,</span></span><span>3A</span></a>, third panel from top). Indeed, levels of cdk6 were not detectable in any of the patient serum samples as compared to a 293T whole cell extract positive control (data not shown). This implies that the presence of cdk4 in the serum is not dependent on the presence or absence of p16<sup>INK4A</sup> and likewise, p16<sup>INK4A</sup> does not affect the expression levels of cdk4 amongst the patient serum samples. The HP1 binding protein was initially identified in the 1D/mass spectrometry analysis in the LTNP low abundance fraction, therefore the serum levels of both HP1&#x003b1; and HP1&#x003b3; subunits were assayed (Figure <a href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3A).</span></span><span>3A</span></a>). The family of heterochromatin-associated proteins exist as three distinct isoforms, &#x003b1;, &#x003b2;, and &#x003b3; and all act as regulators of heterochromatin-mediated transcriptional silencing [<a href="#CR47" rid="CR47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364078">47</a>]. HP1&#x003b1; has been shown to directly interact with DNA methyltransferases and histone methyltransferases to mediate transcriptional silencing [<a href="#CR48" rid="CR48" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364074">48</a>, <a href="#CR49" rid="CR49" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364071">49</a>] and HP1&#x003b3;, in particular, interacts with the histone methyltransferase Suv39H1 to initiate a chromatin-mediated repressive state of the HIV-1 integrated virus [<a href="#CR50" rid="CR50" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364098">50</a>]. HP1&#x003b1; was shown to be present in the low abundance fractions of all of the patient phenotypes whereas HP1&#x003b3; was shown to be present in both the low and high abundant fractions across all patient types (Figure <a href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3A).</span></span><span>3A</span></a>). HP1&#x003b3; is observed in lower amounts in both the Negative and HAART high abundance fractions and all serum samples indicate the presence of a post-translational modification (i.e. a doublet band) as compared to the 293T whole cell extract positive control. This indicates that the HP1&#x003b3; found in serum exists in both a modified and unmodified form. Interestingly, PCTAIRE was present in the highest abundance in the uninfected (Negative), high abundance fraction (Figure <a href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3A,</span></span><span>3A</span></a>, lane 2), however low levels were also seen in both LTNP and HAART high abundance fractions (Figure <a href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3A,</span></span><span>3A</span></a>, lane 4, 6). PCTAIRE was identified initially by mass spectrometry in the high abundance LTNP sample and can be seen in the high abundance fractions of all three of the patient types biochemically, however it is present in lower amounts in the HIV-1 infected patients, indicating that this kinase may be differentially expressed upon infection though not necessarily a unique identifier for infection. P16<sup>INK4A</sup> is the only protein identified from mass spectrometric analysis and confirmed biochemically that is specific for the low abundance LTNP serum samples; although the protein is also identified in the uninfected and the high abundance LTNP fractions. These results are also interesting due to the involvement of p16<sup>INK4A</sup> in alterations of cell cycle control, additionally, mutations in p16<sup>INK4A</sup> are found in various cancers including pancreatic, lymphomas, and sarcomas, contributing to cancer progression [<a href="#CR45" rid="CR45" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364073">45</a>]. These findings also indicate a difference in composition of serum proteins present in HIV-1 infected individuals undergoing HAART treatment versus those that are naturally non-progressing.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig3" co-legend-rid="lgnd_Fig3"><a href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140151277037792" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12981_2010_Article_150_Fig3_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12981_2010_Article_150_Fig3_HTML.jpg" src="/pmc/articles/PMC2908552/bin/12981_2010_Article_150_Fig3_HTML.jpg" /></div><div id="largeobj_idm140151277037792" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2908552/figure/Fig3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig3"><div><a class="figpopup" href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3">Figure 3</a></div><!--caption a7--><div class="caption"><p id="__p19"><strong>Western blot confirmation of MALDI-TOF identified serum proteins</strong>. <strong>A)</strong> Western blots were performed against pooled low (L) and high (H) abundance protein fractions for negative (lanes 2, 3), LTNP (lanes 4, 5), and HAART (lanes 6, 7) patients. Antibodies specific to cdk4, p16<sup>INK4A</sup>, PCTAIRE, HP1&#x003b1;, and HP1&#x003b3; were used. <strong>B)</strong> Western blots were performed against individual patient samples 1-6, low and high abundant LTNPs. Antibodies specific to p16<sup>INK4A</sup> and cdk4 were used. 293T, the pooled low abundance LTNP samples "A," and the pooled high abundance LTNP samples "D" were used as controls. <strong>C)</strong> Immunoprecipitation of p16<sup>INK4A</sup> from the individual low abundant LTNP patient samples, followed by a western blot against p16<sup>INK4A</sup>. HeLa whole cell extract and the pooled low abundance LTNP sample "A" were used as controls.</p></div></div></div><p id="__p20" class="p p-last">In order to address the concern that the protein signature of the pooled set of samples for each patient type may not be an accurate representation of the individual variability that could be present, we screened the low abundance fractions of the LTNPs for the presence of both p16<sup>INK4A</sup> and cdk4. Results in Figure <a href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure3B</span></span><span>3B</span></a> indicate the lack of detection of p16<sup>INK4A</sup> in any of the low abundant LTNP samples, especially as compared to the pooled sample "A" (lane 2). In contrast, p16<sup>INK4A</sup> was detectable in LTNP patients 1 and 2, as well as in the pooled sample "D" for the corresponding high abundance fractions (lanes 2, 3, 4). Due to the nature of the depletion step based on immuno-affinity, it is not surprising that p16<sup>INK4A</sup> is detectable in individual high abundant samples, as it is probably coupled to a larger, more abundant protein and was not efficiently depleted. Additionally, post-depletion, the low abundant fractions for each patient were very dilute and the protein levels were undetectable by traditional methods. Cdk4 was detectable in the LTNP low abundant individual samples with variable abundance, correlating with the data in Figure <a href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure3A.</span></span><span>3A</span></a>. Interestingly, cdk4 was not detectable in the LTNP high abundant individual samples, indicating that this protein was effectively isolated away from the high abundant proteins. Although through a straight western blot, the levels of p16<sup>INK4A</sup> were undetectable, Figure <a href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure3C</span></span><span>3C</span></a> indicates that p16<sup>INK4A</sup> can indeed be immunoprecipitated out of the individual low abundant LTNP samples and subsequently detected by western blot. Lanes 1, 2, and 3 represent the pooled "A" sample and patient samples 2 and 3, respectively. The pooled "A" sample was incubated with &#x003b1;-IgG, and patient samples 2 and 3 were incubated with &#x003b1;-p16. These three immunoprecipitations were subjected to very stringent wash conditions of TNE<sub>600</sub> + 0.1% NP-40, TNE<sub>300</sub> + 0.1% NP-40, and TNE<sub>50</sub> + 0.1% NP-40 in order to remove any non-specific proteins. As can be seen in Figure <a href="/pmc/articles/PMC2908552/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure3C,</span></span><span>3C</span></a>, lanes 1-3 there is some non-specific p16 binding to the &#x003b1;-IgG negative control lane, however, the IPs from the two samples result in much higher percentage of p16<sup>INK4A</sup> present, especially in lane 3. As compared to lanes 4-10, where the salt washes were of less stringency, there are variable levels of p16<sup>INK4A</sup> IPed from each patient sample. Based on the background levels of p16<sup>INK4A</sup> in lane 1, we feel confident in concluding that the patients 2, 3, 4, and 6 have a detectable level of p16<sup>INK4A</sup> only after immunoprecipitation.</p></div><div id="Sec6" class="sec"><h3 id="Sec6title">RT activity of HIV-1 infected cells decreases <em>in vitro</em> in the presence of exogenous p16<sup>INK4A</sup></h3><p id="__p21" class="p p-first-last">Although we have identified p16<sup>INK4A</sup> as differentially present in the serum of HIV-1 infected LTNPs as compared to HAART treated individuals, this may not directly correlate to viral pathogenesis or functionality of this protein. In order to gain insight into the reason why p16<sup>INK4A</sup> may be present preferentially in the serum of LTNP patients, we treated latently infected HIV-1 cell lines (J1.1 and U1) with exogenous purified GST-p16<sup>INK4A</sup> Figure <a href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure4A</span></span><span>4A</span></a> depicts an RT assay which measures the viral reverse transcriptase activity of infected cells and is an indicator of functional particle production. In the presence of both 0.1 and 0.5 ug of GST-p16<sup>INK4A</sup>, J1.1 latently infected T-cells exhibited a decrease in RT activity (cpm) whereas the higher concentration of GST-p16<sup>INK4A</sup> was able to elicit a decrease in RT activity in the latently infected monocytes, U1, as compared to the GST treatment alone. This data suggests that the presence of p16<sup>INK4A</sup> in serum may result in a decrease in viral replication, which may help to explain why the presence of p16<sup>INK4A</sup> in the serum of LTNPs could correlate with an overall lack of viral activity.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig4" co-legend-rid="lgnd_Fig4"><a href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" rid-figpopup="Fig4" rid-ob="ob-Fig4"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140151273529312" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12981_2010_Article_150_Fig4_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12981_2010_Article_150_Fig4_HTML.jpg" src="/pmc/articles/PMC2908552/bin/12981_2010_Article_150_Fig4_HTML.jpg" /></div><div id="largeobj_idm140151273529312" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2908552/figure/Fig4/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig4"><div><a class="figpopup" href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" rid-figpopup="Fig4" rid-ob="ob-Fig4">Figure 4</a></div><!--caption a7--><div class="caption"><p id="__p22"><strong>Viral Replication and Cell Viability assays in the presence of exogenous p16</strong><sup><strong>INK4A</strong></sup>\n<strong>treatment</strong>. <strong>A)</strong> J1.1 and U1 latently infected HIV-1 cell lines were treated with GST or GST-p16<sup>INK4A</sup> (0.1 &#x003bc;g or 0.5 &#x003bc;g). Cell culture supernatants were collected at 48 hours post treatment and assayed for reverse transcriptase (RT) activity measured in cpm. <strong>B)</strong> CEM, Jurkat, H9, and U937 uninfected cell lines were treated with GST or GST-p16<sup>INK4A</sup> (0.1 &#x003bc;g or 0.5 &#x003bc;g). Fourty-eight hours post treatment, the cells were measured for viability with MTT reagent. <strong>C)</strong> Jurkat uninfected T cells were treated with an excess (2.5 &#x003bc;g) of GST or GST-p16<sup>INK4A</sup>. Cells were collected at 48 hours post treatment and western blotted for the presence of Rb and Actin. <strong>D)</strong> CEM, Jurkat, H9, and U937 uninfected cell lines, as well as, J1.1 and U1 latently infected HIV-1 cell lines were assayed for the presence of endogenous levels of p16<sup>INK4A</sup>, cdk4, and Rb. One hundred micrograms of whole cell extract from each cell line was probed with antibodies against p16<sup>INK4A</sup>, cdk4, Rb, and Actin using Western blots. <strong>E)</strong> Uninfected/Infected cell line pairs Jurkat/J1.1 and U937/U1 were treated with GST or GST-p16<sup>INK4A</sup> (0.5 &#x003bc;g) to test for entry of GST-p16 into the cells. Cells were collected at 48 hours post treatment, washed, lysed, and incubated with Glutathione-Sepharose beads overnight. Beads were washed extensively, and probed for the presence of GST-p16<sup>INK4A</sup> by western blot against p16<sup>INK4A</sup>. Arrows indicate the endogenously expressed p16<sup>INK4A</sup> in the control Jurkat lane as well as the larger, GST-p16<sup>INK4A</sup> band.</p></div></div></div></div><div id="Sec7" class="sec"><h3 id="Sec7title">Treatment of uninfected cells with p16<sup>INK4A</sup> does not affect cellular viability</h3><p id="__p23" class="p p-first-last">To detect whether p16<sup>INK4A</sup> had an effect on normal or uninfected cells, we performed an MTT assay to screen for the percentage of cells viable after p16<sup>INK4A</sup> treatment. Figure <a href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure4B</span></span><span>4B</span></a> depicts CEM, Jurkat, and H9 uninfected T-cell lines, as well as the uninfected monocytic U937 cell line treated with GST as well as GST-p16<sup>INK4A</sup>. CEM, H9, and U937 control cells showed no appreciable decrease in cellular viability upon 48 hours of treatment with any of the four conditions. Interestingly, in the presence of 0.5 ug of GST-p16<sup>INK4A</sup>, Jurkat cells exhibit an almost 40% decrease in cellular viability. We next performed western blots on whole cell extracts from all four of these uninfected cell lines and observed only Jurkat cells exhibiting an endogenous expression of p16<sup>INK4A</sup> (Figure <a href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure4D,</span></span><span>4D</span></a>, lane 2). This suggests that the decrease in cellular viability seen in Jurkat cells (Figure <a href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure4B)</span></span><span>4B</span></a>) treated with p16 <sup>INK4A</sup> can be correlated with the expression of exogenous p16<sup>INK4A</sup> in these cells, resulting in an increase in cdk4,6/Cyclin D inhibition and an increase in apoptosis. Interestingly, no endogenous levels of p16<sup>INK4A</sup> are detected in the infected J1.1 cells.</p></div><div id="Sec8" class="sec"><h3 id="Sec8title">Cellular Rb levels decrease as a result of the exogenous addition of p16<sup>INK4A</sup> to Jurkat T cells</h3><p id="__p24" class="p p-first-last">P16<sup>INK4A</sup> is a critical member of the Rb tumor-suppressor pathway which acts to arrest the cell-cycle at G1/S by inhibiting the binding of cdk4/6 to Cyclin D1 and subsequently inhibiting the phosphorylation of Rb. In Figure <a href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure4C,</span></span><span>4C</span></a>, we investigate the levels of Rb present in Jurkat cells alone (lane 1) compared to Jurkat cells treated with an excess of GST or GST-p16<sup>INK4A</sup> (2.5 &#x003bc;g, lanes 2 and 3). Interestingly, upon treatment of exogenous GST-p16<sup>INK4A</sup>, we observed a decrease in cellular levels of Rb; indeed there is also a decrease in Rb with GST treatment alone The Rb antibody used detects total Rb levels in the cell, therefore we could not assume a loss of phosphorylation due to the inhibitory effect of p16<sup>INK4A</sup> on cdk4/6. A recent paper has addressed the literature-wide discrepancies of RB dephosphorylation vs. degradation in response to drug treatment or cell senescence in various cell types [<a href="#CR51" rid="CR51" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364072">51</a>]. It is possible that the increased amount of p16<sup>INK4A</sup> present in these cells has induced a proteasomal degradation of Rb that has not otherwise been characterized in T cells. The cell line panel in Figure <a href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure4D</span></span><span>4D</span></a> was also screened for the presence of endogenous levels of Rb in these cell lines, and interestingly there is a high degree of variability. The T cell lines CEM, Jurkat, and the HIV-1 infected J1.1 have the highest endogenous levels of Rb. Interestingly, the monocytic cell lines U937 and the HIV-1 infected U1 have the lowest amount of Rb present, with almost completely undetectable levels in HIV-1 infected U1 cells. The variability supports the discrepancies seen in the literature about hypo-, hyper-phosphorylation of Rb, as well as depletion or degradation of Rb during cell cycle or cellular responses.</p></div><div id="Sec9" class="sec"><h3 id="Sec9title">Purified GST-p16 is found intracellularly in Jurkat, J1.1, U937, and U1 after treatment</h3><p id="__p25" class="p p-first-last">In order to confirm that the effects seen by GST and GST-p16<sup>INK4A</sup> treatment in Figure <a href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure4A,</span></span><span>4A</span></a>, B, and C, we checked to ensure that the purified proteins are actually entering the cell. Jurkat, J1.1, U937, and U1 cell lines were treated with an excess (2.5 &#x003bc;g) of GST or GST-p16 (Figure <a href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure4E).</span></span><span>4E</span></a>). At 48 hours post treatment, the cells were harvested, washed extensively, lysed, and incubated with Glutathione-Sepharose beads overnight. The Glutathione-Sepharose beads were washed extensively to remove any non-specific proteins with buffers containing salts and detergents. The bound proteins were subjected to Western blot for the presence of p16<sup>INK4A</sup> as shown in Figure <a href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure4E.</span></span><span>4E</span></a>. Jurkat whole cell extract served as the positive control (lanes1 in both blots) and a higher molecular weight band corresponding to GST-p16<sup>INK4a</sup> was observed in the GST-p16<sup>INK4A</sup> pulldown lanes for each of the cell lines (lanes 4 and 7 in both blots). The lack of detection in the untreated cell lysate incubated with beads alone indicates that the protein detected in lanes 5 and 8 are specifically the GST-bound proteins. These studies confirm that the GST proteins are indeed entering the cells when incubated in the extracellular environment.</p></div><div id="Sec10" class="sec"><h3 id="Sec10title">Fascaplysin treatment mimics the exogenous p16<sup>INK4A</sup> treatment</h3><p id="__p26" class="p p-first-last">In order to confirm that the cellular effects shown in Figure <a href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure4</span></span><span>4</span></a> are specific to the natural biological activity of p16<sup>INK4A</sup> as a cdk4/6/Cyclin D inhibitor, we attempted to mimic these studies with the small molecule compound inhibitor Fascaplysin. Fascaplysin (FASC) is a naturally derived molecule isolated from a marine sponge which specifically inhibits the interaction between cdk4/Cyclin D at an IC<sub>50</sub> of approximately 0.35 &#x003bc;M, and to a lesser extent cdk6/Cyclin D by binding the ATP pocket of cdk4, resulting in cell cycle arrest at G1/S [<a href="#CR52" rid="CR52" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364069">52</a>, <a href="#CR53" rid="CR53" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364106">53</a>]. Again, we treated latently infected HIV-1 cell lines (J1.1 and U1) with three concentrations of FASC (100 nM, 500 nM, and 1 &#x003bc;M) and collected supernatants at 24, 48, and 72 hours post treatment. The RT activity of both J1.1 and U1 cells in the presence of FASC decreased over time with increasing concentration of the drug. This indicates that the presence of a general cdk4/Cyclin D inhibitor is able to decrease viral production in the same manner as exogenous p16<sup>INK4A</sup>. Additionally, we performed an MTT assay to screen for the percentage of cells viable after Fascaplysin treatment. Figure <a href="/pmc/articles/PMC2908552/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure5B</span></span><span>5B</span></a> depicts % viability of Jurkat, J1.1, U937, and U1cells treated with three concentrations of FASC (100 nM, 500 nM, and 1 &#x003bc;M) after 48 hours. Correlating with the viability assay presented in Figure <a href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure4B,</span></span><span>4B</span></a>, approximately 50% of Jurkat cells were killed due to additional cdk4/Cyclin D inhibition by 1 &#x003bc;M of FASC treatment. None of the other cell lines exhibit appreciable cell death which indicates that the drug treatment itself is not toxic to the cells. In Figure <a href="/pmc/articles/PMC2908552/figure/Fig5/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig5" rid-ob="ob-Fig5" co-legend-rid="lgnd_Fig5"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure5C,</span></span><span>5C</span></a>, we investigate the levels of Rb present in Jurkat cells alone (lane 1) compared to Jurkat cells that have been treated with three concentrations of FASC (lanes 3, 4, and 5). Again, correlating with our exogenous p16<sup>INK4A</sup> treatment data in Figure <a href="/pmc/articles/PMC2908552/figure/Fig4/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig4" rid-ob="ob-Fig4" co-legend-rid="lgnd_Fig4"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure4,</span></span><span>4</span></a>, we observed a decrease in total cellular Rb levels at the highest concentration of FASC. This set of data confirms that the cellular effects we observed with exogenous p16<sup>INK4A</sup> may be due to the specific cdk inhibitory activity of this molecule. It is interesting to note that these effects are seen with simple protein treatment of the cells with a purified molecule which may not have efficient entry as compared to transfection or drug treatment. This suggests that p16<sup>INK4A</sup> in the serum may be able to enter and exit lymphocytes and exhibit its inhibitory effects during an HIV-1 infection.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig5" co-legend-rid="lgnd_Fig5"><a href="/pmc/articles/PMC2908552/figure/Fig5/" target="figure" rid-figpopup="Fig5" rid-ob="ob-Fig5"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140151268319744" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12981_2010_Article_150_Fig5_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12981_2010_Article_150_Fig5_HTML.jpg" src="/pmc/articles/PMC2908552/bin/12981_2010_Article_150_Fig5_HTML.jpg" /></div><div id="largeobj_idm140151268319744" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2908552/figure/Fig5/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig5"><div><a class="figpopup" href="/pmc/articles/PMC2908552/figure/Fig5/" target="figure" rid-figpopup="Fig5" rid-ob="ob-Fig5">Figure 5</a></div><!--caption a7--><div class="caption"><p id="__p27"><strong>Viral Replication and Cell Viability assays in the presence of the cdk4/6/Cyclin D inhibitor Fascaplysin</strong>. <strong>A)</strong> J1.1 and U1 latently infected HIV-1 cell lines were treated with Fascaplysin (100 nM, 500 nM, or 1 &#x003bc;M). Cell culture supernatants were collected at 48 hours post treatment and assayed for reverse transcriptase (RT) activity measured in cpm. DMSO treatment served as a negative control. <strong>B)</strong> Jurkat, J1.1, U937, and U1 cell lines were treated with Fascaplysin (100 nM, 500 nM, or 1 &#x003bc;M). Fourty-eight hours post treatment, the cells were measured for viability with MTT reagent. DMSO treatment served as a negative control. <strong>C)</strong> Jurkat uninfected T cells were treated with Fascaplysin (100 nM, 500 nM, or 1 &#x003bc;M). Cells were collected at 48 hours post treatment and western blotted for the presence of Rb and Actin. DMSO treatment served as a negative control.</p></div></div></div></div><div id="Sec11" class="sec sec-last"><h3 id="Sec11title">Fascaplysin treatment increases apoptosis in Jurkat cells and arrests latently infected J1.1 cells at G1/S <em>in vitro</em></h3><p id="__p28" class="p p-first-last">We previously showed that both p16<sup>INK4A</sup> and Fascaplysin treatment results in a loss of cellular viability in Jurkat cells as well as a decrease in viral production in infected J1.1 and U1 cells. We were interested to detect the cell cycle pattern of Jurkat, J1.1, U937, and U1 in response to Fascaplysin treatment. Cells were treated with three concentrations of FASC (100 nM, 500 nM, 1 &#x003bc;M) and were collected after 48 hours. Cells were fixed and stained with Propidium Iodide and cell cycle analyzed using a FacsCalibur Flow Cytometer. In Figure <a href="/pmc/articles/PMC2908552/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span>6A-D</span></a>, we compare the population of cells in each stage of the cell cycle at the three concentrations of FASC in Jurkat, J1.1, U937, and U1 cells, as compared to the DMSO control. At the highest concentration of FASC, we observe an increase in the apoptotic peak in Jurkat cells alone. This correlates with the cellular viability data in p16<sup>INK4A</sup> and FASC treated cells. Interestingly, we observed an arrest of cells at G1 in the all of the other treated cell lines. These cell lines do not contain endogenous levels of p16<sup>INK4A</sup>, therefore in the presence of an additional cdk4/6/Cyclin D inhibitor, we observed the normal G1/S arrest effect. There were no major appreciable differences in cell cycle in the FASC treated U937 and U1, however, looking at the protein profile of endogenously expressed p16<sup>INK4A</sup> and Rb, it is not surprising that these monocytic cell lines would exhibit a different inhibitory pathway. Taken together, the cell cycle data shown in Figure <a href="/pmc/articles/PMC2908552/figure/Fig6/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig6" rid-ob="ob-Fig6" co-legend-rid="lgnd_Fig6"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure6,</span></span><span>6</span></a>, supports the overall notion of cdk4/6/Cyclin D inhibitory effect by p16<sup>INK4A</sup> and Fascaplysin.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig6" co-legend-rid="lgnd_Fig6"><a href="/pmc/articles/PMC2908552/figure/Fig6/" target="figure" rid-figpopup="Fig6" rid-ob="ob-Fig6"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm140151271890416" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 12981_2010_Article_150_Fig6_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 12981_2010_Article_150_Fig6_HTML.jpg" src="/pmc/articles/PMC2908552/bin/12981_2010_Article_150_Fig6_HTML.jpg" /></div><div id="largeobj_idm140151271890416" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2908552/figure/Fig6/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig6"><div><a class="figpopup" href="/pmc/articles/PMC2908552/figure/Fig6/" target="figure" rid-figpopup="Fig6" rid-ob="ob-Fig6">Figure 6</a></div><!--caption a7--><div class="caption"><p id="__p29"><strong>Fascaplysin induces apoptosis in Jurkat cells and G1/S arrest in latently infected J1.1 cells</strong>. Cell cycle analysis was performed on <strong>A)</strong> Jurkat, <strong>B)</strong> J1.1, <strong>C)</strong> U937, <strong>D)</strong> U1 that were treated with DMSO, 100 nM, 500 nM, or 1 &#x003bc;M Fascaplysin for 48 hours. Bars represent the percentage of gated cells present in each of the cell cycle stages: G1, S, G2/M or those that had apoptosed.</p></div></div></div></div></div><div id="Sec12" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec12title">Discussion</h2><p id="__p30" class="p p-first">The global proteomic analysis of serum proteins is not without its challenges; however the presence or absence of proteins in such bodily fluids of patients is often the most accurate reflection of cellular leakage or secretion of proteins in response to a disease state. Unfortunately, the classical serum proteome contains a large concentration of high abundance proteins that mask the individual proteins that are unique to a particular phenotype. The identification of such low abundance serum proteins is attractive as a method of early detection of a disease state or a response to infection. Here, we demonstrate that the detection of unique proteins in the serum of HIV-1 infected long-term non-progressors may be indicative of a natural "immunity" to the progression of HIV-1 infection. Specifically, we have identified p16<sup>INK4A</sup>, a cdk4/6 inhibitor, as preferentially present in pooled serum of HIV-1 LTNP patients, as opposed to HIV-1 infected individuals responding to HAART treatment.</p><p id="__p31">P16<sup>INK4A</sup> is a member of the INK4/ARF family of endogenous cdki\'s that serve to regulate cell cycle progression through the inhibition of specific cdk/Cyclin interactions. P16<sup>INK4A</sup> is a critical member of the Rb/p16 tumor-suppressor pathway which inhibits the activation of cdk4/6, preventing the progression through the cell cycle. This tumor-suppressive pathway is mutated in close to 100% of human cancers and specific loss-of-function mutations are found within the <em>Rb</em> gene or the <em>CDKN2A</em> gene encoding p16<sup>INK4A</sup>[<a href="#CR54" rid="CR54" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364103">54</a>]. In addition to the direct inactivation of these two proteins, cancer cells also override this regulatory pathway by overexpressing cdk/Cyclins as well as inducing the endogenous loss of expression of other cdk inhibitors. The loss of p16<sup>INK4A</sup> results in the constitutive activation of cdk4/6 as well as pRb hyperphosphorylation, therefore bypassing the anti-oncogenic senescence induced by this cdk inhibitor. In addition to necessitating an oncogenic state, the regulation and manipulation of cellular cdks and Cyclins is also critical for an active HIV-1 viral infection and occurs mainly through the HIV-1 transactivator Tat. Tat interacts with the cdk2/Cyclin E complex to phosphorylate cdk7 and assist in the phosphorylation of the C-terminal Domain (CTD) of RNA Pol II at the viral LTR (long-terminal repeat) to promote viral transcription [<a href="#CR55" rid="CR55" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364102">55</a>&#x02013;<a href="#CR57" rid="CR57" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364081">57</a>]. Cdk2 is also involved in the direct phosphorylation of Tat at both serine 16 and 46, which are critical for efficient Tat activity [<a href="#CR56" rid="CR56" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364105">56</a>, <a href="#CR57" rid="CR57" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364089">57</a>]. HIV-1 transactivation is also heavily dependent on the recruitment of the cdk9/Cyclin T1 complex to the viral TAR element where it also assists in the phosphorylation of the CTD of RNA Pol II as well as an autophosphorylation event which is important for the localization to the nucleus [<a href="#CR58" rid="CR58" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364070">58</a>]. Taking into consideration the recruitment of cellular kinases for HIV-1 transcription, it is not surprising that pharmacological cdk inhibitors have been developed (analogous to endogenous cdki\'s) as a template to specifically inhibit these kinases. Therefore, the presence of the cdk inhibitor p16<sup>INK4A</sup> in LTNP serum is suggestive of an existing defense mechanism in these patients that imparts a predisposition to a lack of HIV-1 disease progression.</p><p id="__p32">The development of pharmacological cdki\'s and peptide mimetics is a commonly used approach for both cancer and viral therapeutics. For instance, p16<sup>INK4A</sup> peptides have previously been developed, which, when conjugated to localization proteins/peptides, were able to block cell cycle progression in breast cancer and colon cancer cell lines <em>in vitro</em> as well as reduce tumor size in an <em>in vivo</em> mouse model of pancreatic cancer [<a href="#CR59" rid="CR59" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364094">59</a>&#x02013;<a href="#CR61" rid="CR61" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364080">61</a>]. These peptides have also been used for intracellular delivery to leukemia and lymphoma derived cells [<a href="#CR59" rid="CR59" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364076">59</a>, <a href="#CR62" rid="CR62" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364108">62</a>]. These studies have demonstrated the ability of cdki-derived peptides to be used for both direct cell cycle arrest and the treatment of metastatic cancers. This type of therapy is an appropriate approach to cancerous states where the oncogenic mutation results in a loss of function or expression of the p16<sup>INK4A</sup> protein. Here, we show that p16<sup>INK4A</sup> is only endogenously expressed in the Jurkat T-cell line and additional treatment of Jurkat cells with exogenous p16<sup>INK4A</sup> results in a decrease in cellular viability. All additional uninfected and infected cell lines used in this study did not express endogenous levels of p16<sup>INK4A</sup>, suggesting that a loss of function or expression may be present in these particular cell types. More importantly, the treatment of stably infected HIV-1 cell lines, J1.1 and U1, with exogenous p16<sup>INK4A</sup> resulted in a decrease in viral replication with a minimal decrease in cellular viability, suggesting that the presence of p16<sup>INK4A</sup> in the context of an <em>in vitro</em> HIV-1 infection may mimic an <em>in vivo</em> infection in a LTNP patient. The same dosage of p16 <sup>INK4A</sup> needed for a decrease in viral replication in infected cells is not toxic to uninfected cells, with the exception of Jurkat cells, indicating that there may be a threshold for which the effect of this cdk inhibitor begins to harm the cell and potentially induce cell cycle arrest and apoptosis.</p><p id="__p33">In this study we also chose to reinforce the p16<sup>INK4A</sup>-induced cdki effects seen on cellular viability and viral replication with a known cdk4/6/Cyclin D inhibitor, Fascaplysin. We show that treatment of Jurkat cells with this inhibitor also results in a decrease in cellular viability, consistent with the effect seen by treatment with endogenous p16<sup>INK4A</sup>. Additionally, the treatment of both stably infected HIV-1 cell lines, J1.1 and U1, with Fascaplysin resulted in a decrease in viral replication with a minimal decrease in cellular viability. The correlation of this pharmacological cdki inhibitor data with the functional-cdki p16<sup>INK4A</sup> data suggests that the preferential inhibition of the cdk4/6/Cyclin D interaction by LTNPs may contribute to this phenotype.</p><p id="__p34">The high and low abundance fractions analyzed for each of the three patient types were a pooled representation of six individual patient samples that almost certainly have inherent variability. Indeed, when assaying for p16<sup>INK4A</sup> in high and low abundance serum fractions for each individual LTNP patient, p16<sup>INK4A</sup> was present in only a subset of the patients analyzed. This indicates that although p16<sup>INK4A</sup> may serve as a unique serum protein indicating a LTNP HIV-1 infected status, individual person-to-person changes will alter the serum proteome profile and needs to be taken into consideration. Differences in expression of p16<sup>INK4A</sup> can be due to either a host cellular response to the infection or from an influence of the infection itself. Two different scenarios need to be considered when examining the potential importance of this protein in defining a viral disease state such as a LTNP patient; the effect on the host and the effect on the virus.</p><p id="__p35" class="p p-last">Finally, many complicating factors can contribute to the altered state of proteins present in the serum, not the least of which is the length of time in which the patient has been infected, age, gender, coinfections, and other preexisting conditions such as cancer or metabolic diseases. Therefore, it is important to take into consideration some of these factors when applying global proteomic analyses to HIV-1 patient derived samples.</p></div><div id="Sec13" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec13title">Materials and methods</h2><div id="Sec14" class="sec sec-first"><h3 id="Sec14title">Cell Culture and Protein Reagents</h3><p id="__p36" class="p p-first-last">293T endothelial kidney cell line was harvested for whole cell extract and used as a positive control. 293Ts were grown in Dulbecco\'s modified Eagle\'s medium (DMEM) containing 10% FBS, 1% L-glutamine, and 1% streptomycin/penicillin (Quality Biological). Latently infected HIV-1 cell lines J1.1 (T-cells) and U1 (monocytes) were used for RT assays and whole cell extracts were obtained for Western blots. Uninfected CEM, Jurkat, and H9 cell lines (T-cells) and uninfected U937 cell line (monocytes) were used for viability assays and whole cell extracts were obtained for Western blots. Uninfected cells were grown in RPMI-1640 media containing 10% FBS, 1% L-glutamine, and 1% streptomycin/penicillin (Quality Biological). All cells were incubated at 37&#x000b0;C and 5% CO2. GST-p16<sup>INK4A</sup> was a generous gift from Dr. Ming-Daw Tsai, Institute of Biological Chemistry, Academia Sinica, Nankang, Taipei, Taiwan</p></div><div id="Sec15" class="sec"><h3 id="Sec15title">Serum Samples and Serum Depletion</h3><p id="__p37" class="p p-first-last">Eighteen subject serum samples (6 LTNP, 6 HIV infected subjects receiving HAART therapy, and 6 uninfected individuals) were obtained through Washington DC site of the Women\'s Interagency HIV Study (WIHS) (Table <a href="/pmc/articles/PMC2908552/table/Tab1/" target="table" class="fig-table-link figpopup" rid-figpopup="Tab1" rid-ob="ob-Tab1" co-legend-rid=""><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">(Table1).</span></span><span>1</span></a>). WIHS is an NIH multicenter study of the natural history of HIV-1 infection in women [<a href="#CR29" rid="CR29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845364087">29</a>]. LTNPs were defined by WIHS as being HIV Infected, but disease free for at least five years, a CD4 count of greater than 500 at all visits, and no history of anti-retroviral therapy. Serum samples were subjected to depletion of the 12 most abundant serum proteins using the ProteomeLab IgY-12 High Capacity Spin Column Proteome Partitioning kit from Phenomenex (Torrance, CA). This spin column consists of anti-human serum albumin, anti-IgG, anti-fibrinogen, anti-transferrin, anti-IgA, anti-IgM, anti-HDL (anti-apo A-I and anti-apo A-II), anti-haptoglobin, anti-&#x003b1;1-antitrypsin, anti-&#x003b1;1-acid glycoprotein and anti-&#x003b1;2-macroglobulin conjugated to polymeric microbeads. Twenty microliters of each serum sample was diluted 1:25 in dilution buffer and ran over the spin column. Low abundant proteins were collected in the flowthrough and subsequent high abundant, bound proteins were retained and eluted with a low pH stripping buffer. Protein concentrations of both low and high abundant fractions were calculated and pooled as indicated.</p></div><div id="Sec16" class="sec"><h3 id="Sec16title">2D-Gel Electrophoresis (2DGE) and MALDI-TOF MS</h3><p id="__p38" class="p p-first-last">Five hundred micrograms of pooled LTNP, HAART, and Negative patient samples for both Low and High abundance fractions were subjected to isoelectric focusing on an IPG strip, pH 3.0-10.0 and further subjected to SDS-PAGE on a 4-20% Criterion Tris-Glycine gel. The gels were stained with Coomassie Blue and protein spots of interest were excised. Spots were vortexed, washed, and equilibrated in 25 mM NH<sub>4</sub>HCO<sub>3</sub>, broken into smaller pieces, and vortexed and washed 3X with 50% ACN/25 mM NH<sub>4</sub>HCO<sub>3</sub> to remove the Coomassie from the gel. Gel pieces were vortexed and washed with 100% ACN to dehydrate the gel pieces. Gel pieces were re-swelled with up to 200 ng of trypsin (in enough volume to cover the gel) and incubated on ice for 30 min. Residual trypsin was removed, 20 &#x003bc;l of 25 mM NH<sub>4</sub>HCO<sub>3</sub> or enough to cover the gel was added to the gel pieces and the reactions were incubated overnight at 37&#x000b0;C. Peptides were extracted with 1X dH<sub>2</sub>O wash with brief vortexing and sonication, followed by 3X washes with 60% ACN/5% TFA. Extracted peptides were pooled together and a SpeedVac was utilized to reduce the volume to approximately 10 &#x003bc;l. Twenty microliters of 0.1% TFA was added to each tube and peptides were desalted using C<sub>18</sub> ZipTips (Millipore) according to manufacturer\'s instructions. Peptides were spotted on MALDI sample plate 1:1 with &#x003b1;-cyano-4-hydroxy cinnamic acid (CHCA) matrix solution: 10 mg CHCA, 500 &#x003bc;l 100% ACN, 500 &#x003bc;l 0.1% TFA. Positive control calibration peptide solution of Bradykinin, Angiotensin II, P<sub>14</sub>R, and ACTH was spotted along with negative control empty gel slice. Mass peaks obtained were entered into Mascot <a href="http://www.matrixscience.com/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://www.matrixscience.com/</a> and ProFound <a href="http://prowl.rockefeller.edu/prowl-cgi/profound.exe" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CBody&amp;TO=External%7CLink%7CURI" target="_blank">http://prowl.rockefeller.edu/prowl-cgi/profound.exe</a> databases for peptide mass fingerprinting analysis.</p></div><div id="Sec17" class="sec"><h3 id="Sec17title">Immunoprecipitations</h3><p id="__p39" class="p p-first-last">Fifty microliters of pooled low abundance LTNP serum sample "A" and individual low abundance LTNP serum samples (1-6) were incubated with either &#x003b1;-IgG or &#x003b1;-p16<sup>INK4A</sup> as indicated, volume was brought up to 500 &#x003bc;l with TNE<sub>50</sub> + 0.1% NP-40, rotating overnight at 4&#x000b0;C. Extracts were incubated with 50 &#x003bc;l of a 30% slurry of Protein A + G Agarose beads (Calbiochem #IP05) for 2 hrs, rotating, at 4&#x000b0;C. Beads were washed with indicated salt washes (TNE<sub>600</sub> + 0.1% NP-40, TNE<sub>300</sub> + 0.1% NP-40, TNE<sub>150</sub> + 0.1% NP-40, or TNE<sub>50</sub> + 0.1% NP-40), bound proteins were removed from the beads with Laemmli buffer and subjected to Western blots against p16<sup>INK4A</sup>.</p></div><div id="Sec18" class="sec"><h3 id="Sec18title">Western Blots</h3><p id="__p40" class="p p-first-last">Western blots were performed to validate proteins identified from depleted serum samples. Whole cell extracts were obtained from cell culture pellets washed twice with 25 mL of phosphate buffered saline (PBS) with Ca2+ and Mg2+ (Quality Biological) and centrifuged once more. Cell pellets were resuspended in lysis buffer (50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 5 mM EDTA, 0.5% NP-40, 50 mM NaF, 0.2 mM Na3VO4, 1 mM DTT, one complete protease cocktail tablet/50 mL) and incubated on ice for 20 min, with a gently vortexing every 5 min. Cell lysates were transferred to eppendorf tubes and were centrifuged at 10,000 rpm for 10 min. Supernatants were transferred to a fresh tube where protein concentrations were determined using Bio-Rad protein assay (Bio-Rad, Hercules, CA). Antibodies against cdk4 (sc-749), p16 (sc-467), PCTAIRE (sc-174), Rb (sc-50), and Actin (sc-1615) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against HP1&#x003b1; and HP1&#x003b3; were purchased from Cell Signaling (Danvers, MA).</p></div><div id="Sec19" class="sec"><h3 id="Sec19title">RT Assays</h3><p id="__p41" class="p p-first-last">J1.1 and U1 cells (2 &#x000d7; 10<sup>6</sup>) were treated with GST or GST-p16 (0.1 or 0.5 &#x003bc;g) or Fascaplysin (100 nM, 500 nM, or 1 &#x003bc;M) and supernatants collected to test for the presence of virus 48 hours post treatment. Jurkats were treated with GST or GST-p16 (2.5 &#x003bc;g) for 48 hours prior to HIV-1 infection with the dual tropic strain 89.6. Supernatants were collected at various time points post infection to test for the presence of virus post treatment. Viral supernatants (10 &#x003bc;l) were incubated in a 96-well plate with reverse transcriptase (RT) reaction mixture containing 1X RT buffer (50 mM Tris-HCl, 1 mM DTT, 5 mM MgCl<sub>2</sub>, 20 mM KCl), 0.1% Triton, poly(A) (1U/ml), pd(T) (1U/ml), and [3H]TTP. The mixture was incubated overnight at 37&#x000b0;C, and 5 &#x003bc;l of the reaction mix was spotted on a DEAE Filtermat paper, washed four times with 5% Na<sub>2</sub>HPO<sub>4</sub>, three times with water, and then dried completely. RT activity was measured in a Betaplate counter (Wallac, Gaithersburg, MD).</p></div><div id="Sec20" class="sec"><h3 id="Sec20title">MTT Assays</h3><p id="__p42" class="p p-first-last">Five thousand cells were plated per well in a 96-well plate and the next day cells were treated with GST or GST-p16 (0.1 or 0.5 &#x003bc;g) or Fascaplysin (100 nM, 500 nM, or 1 &#x003bc;M). Forty-eight hours later, 10 &#x003bc;l MTT reagent (5 mg/ml) was added to each well and plates incubated at 37&#x000b0;C for 3 hours. Next, 100 &#x003bc;l of DMSO was added to each well to solubilize the violet crystals. The assay was read at 570 nM.</p></div><div id="Sec21" class="sec sec-last"><h3 id="Sec21title">Cell cycle analysis</h3><p id="__p43" class="p p-first-last">Cells were washed with PBS and fixed with 70% ethanol. Following rehydration in PBS, cells were stained in PBS containing 25 ug/ml propidium iodide (Sigma), 10 ug/ml RNase A (Sigma) and 0.1% NP-40. Cells were analyzed on a BD FacsCalibur flow cytometer. Cell cycle analysis and measurement of apoptosis was performed using CellQuest software. Aggregates and debris were excluded by gating on the FL2W and FL2A parameters. Apoptosis was considered to be the population of cells that were sub-G1.</p></div></div><div id="idm140151272456608" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140151272456608title">Acknowledgements</h2><div class="sec"><p id="__p57">We would like to thank the members of the Kashanchi lab for experiments and assistance with the manuscript. We thank Dr. Ming-Daw Tsai (Institute of Biological Chemistry, Academia Sinica) for the GST-p16<sup>INK4A</sup> plasmid constructs. Most of the data on the current manuscript was generated using funds from NIH grants AI078859, AI074410 and AI043894. Data in this manuscript were collected by the Women\'s Interagency HIV Study (WIHS) Collaborative Study Group with centers (Principal Investigators) at New York City/Bronx Consortium (Kathryn Anastos); Brooklyn, NY (Howard Minkoff); Washington, DC Metropolitan Consortium (Mary Young); The Connie Wofsy Study Consortium of Northern California (Ruth Greenblatt); Los Angeles County/Southern California Consortium (Alexandra Levine); Chicago Consortium (Mardge Cohen); Data Coordinating Center (Stephen Gange). The WIHS is funded by the National Institute of Allergy and Infectious Diseases (UO1-AI-35004, UO1-AI-31834, UO1-AI-34994, UO1-AI-34989, UO1-AI-34993, and UO1-AI-42590) and by the <em>Eunice Kennedy Shriver</em> National Institute of Child Health and Human Development (UO1-HD-32632). The study is co-funded by the National Cancer Institute, the National Institute on Drug Abuse, and the National Institute on Deafness and Other Communication Disorders. Funding is also provided by the National Center for Research Resources (UCSF-CTSI Grant Number UL1 RR024131). The contents of this publication are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health. Rachel Van Duyne is a predoctoral student in the Microbiology and Immunology Program of the Institute for Biomedical Sciences at The George Washington University.</p></div></div><div id="App1" class="tsec sec headless whole_rhythm"><!--/article/back/app-group/app/--><div id="Sec22" class="sec sec-first"><h3 id="Sec22title">Authors&#x02019; original submitted files for images</h3><p id="__p44" class="p p-first-last">Below are the links to the authors&#x02019; original submitted files for images.<span class="sup-box" id="MOESM1"><a href="/pmc/articles/PMC2908552/bin/12981_2010_150_MOESM1_ESM.ppt" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 1</a><sup>(383K, ppt)</sup></span><span class="sup-box" id="MOESM2"><a href="/pmc/articles/PMC2908552/bin/12981_2010_150_MOESM2_ESM.ppt" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 2</a><sup>(338K, ppt)</sup></span><span class="sup-box" id="MOESM3"><a href="/pmc/articles/PMC2908552/bin/12981_2010_150_MOESM3_ESM.ppt" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 3</a><sup>(1.7M, ppt)</sup></span><span class="sup-box" id="MOESM4"><a href="/pmc/articles/PMC2908552/bin/12981_2010_150_MOESM4_ESM.ppt" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 4</a><sup>(394K, ppt)</sup></span><span class="sup-box" id="MOESM5"><a href="/pmc/articles/PMC2908552/bin/12981_2010_150_MOESM5_ESM.ppt" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 5</a><sup>(291K, ppt)</sup></span><span class="sup-box" id="MOESM6"><a href="/pmc/articles/PMC2908552/bin/12981_2010_150_MOESM6_ESM.ppt" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 6</a><sup>(235K, ppt)</sup></span><span class="sup-box" id="MOESM7"><a href="/pmc/articles/PMC2908552/bin/12981_2010_150_MOESM7_ESM.ppt" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 7</a><sup>(289K, ppt)</sup></span><span class="sup-box" id="MOESM8"><a href="/pmc/articles/PMC2908552/bin/12981_2010_150_MOESM8_ESM.ppt" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 8</a><sup>(233K, ppt)</sup></span></p></div></div><div id="idm140151272460240" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140151272460240title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm140151272460112"><p id="__p53" class="p p-first"><strong>Competing interests</strong></p><p id="__p54" class="p p-last">The authors declare that they have no competing interests.</p></p><p class="fn sec" id="idm140151272458704"><p id="__p55" class="p p-first"><strong>Authors\' contributions</strong></p><p id="__p56" class="p p-last">RVD performed the serum depletion, 2D gel analysis, MALDI preparation, and mass spectrometry analysis as well as the drafting of the manuscript. IG performed serum depletion, MALDI preparation, and confirmatory western blots. KKH performed the RT and MTT assays. RE performed the MALDI preparation and analysis. ZK provided support in drafting the manuscript and MALDI analysis. CL established the patient definitions (LTNP, HAART responders, etc.) and patient sample identification. MY is the WIHS contact and provided support and information on patient samples. FK provided overall direction and funding for the project. All authors have read and approved the final manuscript.</p></p></div></div><div id="idm140151272537792aff-info" class="tsec sec"><h2 class="head no_bottom_margin" id="idm140151272537792aff-infotitle">Contributor Information</h2><p><span class="fm-affl">Rachel Van Duyne, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmuwg@vvrmcb" class="oemail">ude.cmuwg@vvrmcb</a></span>.</p><p><span class="fm-affl">Irene Guendel, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.umg@ledneugi" class="oemail">ude.umg@ledneugi</a></span>.</p><p><span class="fm-affl">Kylene Kehn-Hall, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.umg@lahnhekk" class="oemail">ude.umg@lahnhekk</a></span>.</p><p><span class="fm-affl">Rebecca Easley, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.liamg@lsaelr" class="oemail">moc.liamg@lsaelr</a></span>.</p><p><span class="fm-affl">Zachary Klase, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.diain@azesalk" class="oemail">vog.hin.diain@azesalk</a></span>.</p><p><span class="fm-affl">Chenglong Liu, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.nwotegroeg@872lc" class="oemail">ude.nwotegroeg@872lc</a></span>.</p><p><span class="fm-affl">Mary Young, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.nwotegroeg@amgnuoy" class="oemail">ude.nwotegroeg@amgnuoy</a></span>.</p><p><span class="fm-affl">Fatah Kashanchi, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.cmuwg@kxfmcb" class="oemail">ude.cmuwg@kxfmcb</a></span>.</p></div><div id="Bib1" class="tsec sec"><h2 class="head no_bottom_margin" id="Bib1title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="CR1">1. <span class="element-citation">Adkins JN, Varnum SM, Auberry KJ, Moore RJ, Angell NH, Smith RD, Springer DL, Pounds JG. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. <span><span class="ref-journal">Mol Cell Proteomics. </span>2002;<span class="ref-vol">1</span>:947\xe2\x80\x93955. doi: 10.1074/mcp.M200066-MCP200.</span> [<a href="/pubmed/12543931" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1074%2Fmcp.M200066-MCP200" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell+Proteomics&amp;title=Toward+a+human+blood+serum+proteome:+analysis+by+multidimensional+separation+coupled+with+mass+spectrometry&amp;author=JN+Adkins&amp;author=SM+Varnum&amp;author=KJ+Auberry&amp;author=RJ+Moore&amp;author=NH+Angell&amp;volume=1&amp;publication_year=2002&amp;pages=947-955&amp;pmid=12543931&amp;doi=10.1074/mcp.M200066-MCP200&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR2">2. <span class="element-citation">Tanaka Y, Akiyama H, Kuroda T, Jung G, Tanahashi K, Sugaya H, Utsumi J, Kawasaki H, Hirano H. A novel approach and protocol for discovering extremely low-abundance proteins in serum. <span><span class="ref-journal">Proteomics. </span>2006;<span class="ref-vol">6</span>:4845\xe2\x80\x934855. doi: 10.1002/pmic.200500774.</span> [<a href="/pubmed/16878292" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1002%2Fpmic.200500774" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proteomics&amp;title=A+novel+approach+and+protocol+for+discovering+extremely+low-abundance+proteins+in+serum&amp;author=Y+Tanaka&amp;author=H+Akiyama&amp;author=T+Kuroda&amp;author=G+Jung&amp;author=K+Tanahashi&amp;volume=6&amp;publication_year=2006&amp;pages=4845-4855&amp;pmid=16878292&amp;doi=10.1002/pmic.200500774&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR3">3. <span class="element-citation">Sasaki K, Sato K, Akiyama Y, Yanagihara K, Oka M, Yamaguchi K. Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. <span><span class="ref-journal">Cancer Res. </span>2002;<span class="ref-vol">62</span>:4894\xe2\x80\x934898.</span> [<a href="/pubmed/12208737" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Peptidomics-based+approach+reveals+the+secretion+of+the+29-residue+COOH-terminal+fragment+of+the+putative+tumor+suppressor+protein+DMBT1+from+pancreatic+adenocarcinoma+cell+lines&amp;author=K+Sasaki&amp;author=K+Sato&amp;author=Y+Akiyama&amp;author=K+Yanagihara&amp;author=M+Oka&amp;volume=62&amp;publication_year=2002&amp;pages=4894-4898&amp;pmid=12208737&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR4">4. <span class="element-citation">Kennedy S. The role of proteomics in toxicology: identification of biomarkers of toxicity by protein expression analysis. <span><span class="ref-journal">Biomarkers. </span>2002;<span class="ref-vol">7</span>:269\xe2\x80\x93290. doi: 10.1080/13547500210127318.</span> [<a href="/pubmed/12171755" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1080%2F13547500210127318" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biomarkers&amp;title=The+role+of+proteomics+in+toxicology:+identification+of+biomarkers+of+toxicity+by+protein+expression+analysis&amp;author=S+Kennedy&amp;volume=7&amp;publication_year=2002&amp;pages=269-290&amp;pmid=12171755&amp;doi=10.1080/13547500210127318&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR5">5. <span class="element-citation">Jacobs JM, Adkins JN, Qian WJ, Liu T, Shen Y, Camp DG, Smith RD. Utilizing human blood plasma for proteomic biomarker discovery. <span><span class="ref-journal">J Proteome Res. </span>2005;<span class="ref-vol">4</span>:1073\xe2\x80\x931085. doi: 10.1021/pr0500657.</span> [<a href="/pubmed/16083256" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1021%2Fpr0500657" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Proteome+Res&amp;title=Utilizing+human+blood+plasma+for+proteomic+biomarker+discovery&amp;author=JM+Jacobs&amp;author=JN+Adkins&amp;author=WJ+Qian&amp;author=T+Liu&amp;author=Y+Shen&amp;volume=4&amp;publication_year=2005&amp;pages=1073-1085&amp;pmid=16083256&amp;doi=10.1021/pr0500657&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR6">6. <span class="element-citation">Ardekani AM, Liotta LA, Petricoin EF. Clinical potential of proteomics in the diagnosis of ovarian cancer. <span><span class="ref-journal">Expert Rev Mol Diagn. </span>2002;<span class="ref-vol">2</span>:312\xe2\x80\x93320. doi: 10.1586/14737159.2.4.312.</span> [<a href="/pubmed/12138495" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1586%2F14737159.2.4.312" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Rev+Mol+Diagn&amp;title=Clinical+potential+of+proteomics+in+the+diagnosis+of+ovarian+cancer&amp;author=AM+Ardekani&amp;author=LA+Liotta&amp;author=EF+Petricoin&amp;volume=2&amp;publication_year=2002&amp;pages=312-320&amp;pmid=12138495&amp;doi=10.1586/14737159.2.4.312&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR7">7. <span class="element-citation">Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. <span><span class="ref-journal">Mol Cell Proteomics. </span>2004;<span class="ref-vol">3</span>:355\xe2\x80\x93366. doi: 10.1074/mcp.R400006-MCP200.</span> [<a href="/pubmed/14764655" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1074%2Fmcp.R400006-MCP200" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell+Proteomics&amp;title=Progress+and+challenges+in+screening+for+early+detection+of+ovarian+cancer&amp;author=IJ+Jacobs&amp;author=U+Menon&amp;volume=3&amp;publication_year=2004&amp;pages=355-366&amp;pmid=14764655&amp;doi=10.1074/mcp.R400006-MCP200&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR8">8. <span class="element-citation">Rosenblatt KP, Bryant-Greenwood P, Killian JK, Mehta A, Geho D, Espina V, Petricoin EF, Liotta LA. Serum proteomics in cancer diagnosis and management. <span><span class="ref-journal">Annu Rev Med. </span>2004;<span class="ref-vol">55</span>:97\xe2\x80\x93112. doi: 10.1146/annurev.med.55.091902.105237.</span> [<a href="/pubmed/14746511" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1146%2Fannurev.med.55.091902.105237" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Annu+Rev+Med&amp;title=Serum+proteomics+in+cancer+diagnosis+and+management&amp;author=KP+Rosenblatt&amp;author=P+Bryant-Greenwood&amp;author=JK+Killian&amp;author=A+Mehta&amp;author=D+Geho&amp;volume=55&amp;publication_year=2004&amp;pages=97-112&amp;pmid=14746511&amp;doi=10.1146/annurev.med.55.091902.105237&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR9">9. <span class="element-citation">Lathrop JT, Anderson NL, Anderson NG, Hammond DJ. Therapeutic potential of the plasma proteome. <span><span class="ref-journal">Curr Opin Mol Ther. </span>2003;<span class="ref-vol">5</span>:250\xe2\x80\x93257.</span> [<a href="/pubmed/12870434" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+Opin+Mol+Ther&amp;title=Therapeutic+potential+of+the+plasma+proteome&amp;author=JT+Lathrop&amp;author=NL+Anderson&amp;author=NG+Anderson&amp;author=DJ+Hammond&amp;volume=5&amp;publication_year=2003&amp;pages=250-257&amp;pmid=12870434&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR10">10. <span class="element-citation">Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. <span><span class="ref-journal">Mol Cell Proteomics. </span>2002;<span class="ref-vol">1</span>:845\xe2\x80\x93867. doi: 10.1074/mcp.R200007-MCP200.</span> [<a href="/pubmed/12488461" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1074%2Fmcp.R200007-MCP200" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell+Proteomics&amp;title=The+human+plasma+proteome:+history,+character,+and+diagnostic+prospects&amp;author=NL+Anderson&amp;author=NG+Anderson&amp;volume=1&amp;publication_year=2002&amp;pages=845-867&amp;pmid=12488461&amp;doi=10.1074/mcp.R200007-MCP200&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR11">11. <span class="element-citation">Zhang Z, Bast RC, Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. <span><span class="ref-journal">Cancer Res. </span>2004;<span class="ref-vol">64</span>:5882\xe2\x80\x935890. doi: 10.1158/0008-5472.CAN-04-0746.</span> [<a href="/pubmed/15313933" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1158%2F0008-5472.CAN-04-0746" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Three+biomarkers+identified+from+serum+proteomic+analysis+for+the+detection+of+early+stage+ovarian+cancer&amp;author=Z+Zhang&amp;author=RC+Bast&amp;author=Y+Yu&amp;author=J+Li&amp;author=LJ+Sokoll&amp;volume=64&amp;publication_year=2004&amp;pages=5882-5890&amp;pmid=15313933&amp;doi=10.1158/0008-5472.CAN-04-0746&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR12">12. <span class="element-citation">Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. <span><span class="ref-journal">Gynecol Oncol. </span>2003;<span class="ref-vol">88</span>:S152\xe2\x80\x93157. doi: 10.1006/gyno.2002.6708.</span> [<a href="/pubmed/12586109" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1006%2Fgyno.2002.6708" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gynecol+Oncol&amp;title=Current+status+of+the+molecular+characterization+of+the+ovarian+cancer+antigen+CA125+and+implications+for+its+use+in+clinical+screening&amp;author=C+Whitehouse&amp;author=E+Solomon&amp;volume=88&amp;publication_year=2003&amp;pages=S152-157&amp;pmid=12586109&amp;doi=10.1006/gyno.2002.6708&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR13">13. <span class="element-citation">Grossklaus DJ, Smith JA, Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. The free/total prostate-specific antigen ratio (%fPSA) is the best predictor of tumor involvement in the radical prostatectomy specimen among men with an elevated PSA. <span><span class="ref-journal">Urol Oncol. </span>2002;<span class="ref-vol">7</span>:195\xe2\x80\x93198. doi: 10.1016/S1078-1439(02)00190-4.</span> [<a href="/pubmed/12644216" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS1078-1439(02)00190-4" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Urol+Oncol&amp;title=The+free/total+prostate-specific+antigen+ratio+(%fPSA)+is+the+best+predictor+of+tumor+involvement+in+the+radical+prostatectomy+specimen+among+men+with+an+elevated+PSA&amp;author=DJ+Grossklaus&amp;author=JA+Smith&amp;author=SB+Shappell&amp;author=CS+Coffey&amp;author=SS+Chang&amp;volume=7&amp;publication_year=2002&amp;pages=195-198&amp;pmid=12644216&amp;doi=10.1016/S1078-1439(02)00190-4&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR14">14. <span class="element-citation">Liu Z, Tian Y, Wang B, Yan Z, Qian D, Ding S, Song X, Bai Z, Li L. Serum proteomics with SELDI-TOF-MS in congenital human cytomegalovirus hepatitis. <span><span class="ref-journal">J Med Virol. </span>2007;<span class="ref-vol">79</span>:1500\xe2\x80\x931505. doi: 10.1002/jmv.20927.</span> [<a href="/pubmed/17705191" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1002%2Fjmv.20927" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Med+Virol&amp;title=Serum+proteomics+with+SELDI-TOF-MS+in+congenital+human+cytomegalovirus+hepatitis&amp;author=Z+Liu&amp;author=Y+Tian&amp;author=B+Wang&amp;author=Z+Yan&amp;author=D+Qian&amp;volume=79&amp;publication_year=2007&amp;pages=1500-1505&amp;pmid=17705191&amp;doi=10.1002/jmv.20927&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR15">15. <span class="element-citation">Pang RT, Poon TC, Chan KC, Lee NL, Chiu RW, Tong YK, Wong RM, Chim SS, Ngai SM, Sung JJ, Lo YM. Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. <span><span class="ref-journal">Clin Chem. </span>2006;<span class="ref-vol">52</span>:421\xe2\x80\x93429. doi: 10.1373/clinchem.2005.061689.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC7108167/">PMC free article</a>]</span> [<a href="/pubmed/16423906" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1373%2Fclinchem.2005.061689" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Chem&amp;title=Serum+proteomic+fingerprints+of+adult+patients+with+severe+acute+respiratory+syndrome&amp;author=RT+Pang&amp;author=TC+Poon&amp;author=KC+Chan&amp;author=NL+Lee&amp;author=RW+Chiu&amp;volume=52&amp;publication_year=2006&amp;pages=421-429&amp;pmid=16423906&amp;doi=10.1373/clinchem.2005.061689&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR16">16. <span class="element-citation">Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. The HCV serum proteome: a search for fibrosis protein markers. <span><span class="ref-journal">J Viral Hepat. </span>2009;<span class="ref-vol">16</span>:418\xe2\x80\x93429. doi: 10.1111/j.1365-2893.2009.01083.x.</span> [<a href="/pubmed/19226329" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1111%2Fj.1365-2893.2009.01083.x" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Viral+Hepat&amp;title=The+HCV+serum+proteome:+a+search+for+fibrosis+protein+markers&amp;author=KJ+Cheung&amp;author=K+Tilleman&amp;author=D+Deforce&amp;author=I+Colle&amp;author=H+Van+Vlierberghe&amp;volume=16&amp;publication_year=2009&amp;pages=418-429&amp;pmid=19226329&amp;doi=10.1111/j.1365-2893.2009.01083.x&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR17">17. <span class="element-citation">Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RA. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. <span><span class="ref-journal">Nat Med. </span>1996;<span class="ref-vol">2</span>:1240\xe2\x80\x931243. doi: 10.1038/nm1196-1240.</span> [<a href="/pubmed/8898752" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2Fnm1196-1240" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Med&amp;title=The+role+of+a+mutant+CCR5+allele+in+HIV-1+transmission+and+disease+progression&amp;author=Y+Huang&amp;author=WA+Paxton&amp;author=SM+Wolinsky&amp;author=AU+Neumann&amp;author=L+Zhang&amp;volume=2&amp;publication_year=1996&amp;pages=1240-1243&amp;pmid=8898752&amp;doi=10.1038/nm1196-1240&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR18">18. <span class="element-citation">Yamada T, Iwamoto A. Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection. <span><span class="ref-journal">Arch Virol. </span>2000;<span class="ref-vol">145</span>:1021\xe2\x80\x931027. doi: 10.1007/s007050050692.</span> [<a href="/pubmed/10881687" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1007%2Fs007050050692" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arch+Virol&amp;title=Comparison+of+proviral+accessory+genes+between+long-term+nonprogressors+and+progressors+of+human+immunodeficiency+virus+type+1+infection&amp;author=T+Yamada&amp;author=A+Iwamoto&amp;volume=145&amp;publication_year=2000&amp;pages=1021-1027&amp;pmid=10881687&amp;doi=10.1007/s007050050692&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR19">19. <span class="element-citation">Mologni D, Citterio P, Menzaghi B, Zanone Poma B, Riva C, Broggini V, Sinicco A, Milazzo L, Adorni F, Rusconi S, Galli M, Riva A. Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients. <span><span class="ref-journal">Aids. </span>2006;<span class="ref-vol">20</span>:567\xe2\x80\x93574. doi: 10.1097/01.aids.0000210611.60459.0e.</span> [<a href="/pubmed/16470121" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1097%2F01.aids.0000210611.60459.0e" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Aids&amp;title=Vpr+and+HIV-1+disease+progression:+R77Q+mutation+is+associated+with+long-term+control+of+HIV-1+infection+in+different+groups+of+patients&amp;author=D+Mologni&amp;author=P+Citterio&amp;author=B+Menzaghi&amp;author=B+Zanone+Poma&amp;author=C+Riva&amp;volume=20&amp;publication_year=2006&amp;pages=567-574&amp;pmid=16470121&amp;doi=10.1097/01.aids.0000210611.60459.0e&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR20">20. <span class="element-citation">Lum JJ, Cohen OJ, Nie Z, Weaver JG, Gomez TS, Yao XJ, Lynch D, Pilon AA, Hawley N, Kim JE, Chen Z, Montpetit M, Sanchez-Dardon J, Cohen EA, Badley AD. Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. <span><span class="ref-journal">J Clin Invest. </span>2003;<span class="ref-vol">111</span>:1547\xe2\x80\x931554. doi: 10.1172/JCI16233.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC155040/">PMC free article</a>]</span> [<a href="/pubmed/12750404" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1172%2FJCI16233" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Invest&amp;title=Vpr+R77Q+is+associated+with+long-term+nonprogressive+HIV+infection+and+impaired+induction+of+apoptosis&amp;author=JJ+Lum&amp;author=OJ+Cohen&amp;author=Z+Nie&amp;author=JG+Weaver&amp;author=TS+Gomez&amp;volume=111&amp;publication_year=2003&amp;pages=1547-1554&amp;pmid=12750404&amp;doi=10.1172/JCI16233&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR21">21. <span class="element-citation">Kestler HW, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, Desrosiers RC. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. <span><span class="ref-journal">Cell. </span>1991;<span class="ref-vol">65</span>:651\xe2\x80\x93662. doi: 10.1016/0092-8674(91)90097-I.</span> [<a href="/pubmed/2032289" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2F0092-8674(91)90097-I" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Importance+of+the+nef+gene+for+maintenance+of+high+virus+loads+and+for+development+of+AIDS&amp;author=HW+Kestler&amp;author=DJ+Ringler&amp;author=K+Mori&amp;author=DL+Panicali&amp;author=PK+Sehgal&amp;volume=65&amp;publication_year=1991&amp;pages=651-662&amp;pmid=2032289&amp;doi=10.1016/0092-8674(91)90097-I&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR22">22. <span class="element-citation">Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, Chatfield C, Lawson VA, Crowe S, Maerz A, Sonza S, Learmont J, Sullivan JS, Cunningham A, Dwyer D, Dowton D, Mills J. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. <span><span class="ref-journal">Science. </span>1995;<span class="ref-vol">270</span>:988\xe2\x80\x93991. doi: 10.1126/science.270.5238.988.</span> [<a href="/pubmed/7481804" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1126%2Fscience.270.5238.988" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Genomic+structure+of+an+attenuated+quasi+species+of+HIV-1+from+a+blood+transfusion+donor+and+recipients&amp;author=NJ+Deacon&amp;author=A+Tsykin&amp;author=A+Solomon&amp;author=K+Smith&amp;author=M+Ludford-Menting&amp;volume=270&amp;publication_year=1995&amp;pages=988-991&amp;pmid=7481804&amp;doi=10.1126/science.270.5238.988&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR23">23. <span class="element-citation">Stewart GJ, Ashton LJ, Biti RA, Ffrench RA, Bennetts BH, Newcombe NR, Benson EM, Carr A, Cooper DA, Kaldor JM. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group. <span><span class="ref-journal">Aids. </span>1997;<span class="ref-vol">11</span>:1833\xe2\x80\x931838. doi: 10.1097/00002030-199715000-00007.</span> [<a href="/pubmed/9412701" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1097%2F00002030-199715000-00007" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Aids&amp;title=Increased+frequency+of+CCR-5+delta+32+heterozygotes+among+long-term+non-progressors+with+HIV-1+infection.+The+Australian+Long-Term+Non-Progressor+Study+Group&amp;author=GJ+Stewart&amp;author=LJ+Ashton&amp;author=RA+Biti&amp;author=RA+Ffrench&amp;author=BH+Bennetts&amp;volume=11&amp;publication_year=1997&amp;pages=1833-1838&amp;pmid=9412701&amp;doi=10.1097/00002030-199715000-00007&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR24">24. <span class="element-citation">Mazzucchelli R, Corvasce S, Violin M, Riva C, Bianchi R, Deho L, Velleca R, Cibella J, Bada M, Moroni M, Galli M, Balotta C. Role of CCR5, CCR2 and SDF-1 gene polymorphisms in a population of HIV-1 infected individuals. <span><span class="ref-journal">J Biol Regul Homeost Agents. </span>2001;<span class="ref-vol">15</span>:265\xe2\x80\x93271.</span> [<a href="/pubmed/11693435" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Regul+Homeost+Agents&amp;title=Role+of+CCR5,+CCR2+and+SDF-1+gene+polymorphisms+in+a+population+of+HIV-1+infected+individuals&amp;author=R+Mazzucchelli&amp;author=S+Corvasce&amp;author=M+Violin&amp;author=C+Riva&amp;author=R+Bianchi&amp;volume=15&amp;publication_year=2001&amp;pages=265-271&amp;pmid=11693435&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR25">25. <span class="element-citation">Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O\'Brien SJ. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. <span><span class="ref-journal">Science. </span>1996;<span class="ref-vol">273</span>:1856\xe2\x80\x931862. doi: 10.1126/science.273.5283.1856.</span> [<a href="/pubmed/8791590" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1126%2Fscience.273.5283.1856" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Genetic+restriction+of+HIV-1+infection+and+progression+to+AIDS+by+a+deletion+allele+of+the+CKR5+structural+gene.+Hemophilia+Growth+and+Development+Study,+Multicenter+AIDS+Cohort+Study,+Multicenter+Hemophilia+Cohort+Study,+San+Francisco+City+Cohort,+ALIVE+Study&amp;author=M+Dean&amp;author=M+Carrington&amp;author=C+Winkler&amp;author=GA+Huttley&amp;author=MW+Smith&amp;volume=273&amp;publication_year=1996&amp;pages=1856-1862&amp;pmid=8791590&amp;doi=10.1126/science.273.5283.1856&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR26">26. <span class="element-citation">Munkanta M, Terunuma H, Takahashi M, Hanabusa H, Miura T, Ikeda S, Sakai M, Fujii T, Takahashi Y, Oka S, Matsuda J, Ishikawa M, Taki M, Takashima Y, Mimaya J, Ito M, Kimura A, Yasunami M. HLA-B polymorphism in Japanese HIV-1-infected long-term surviving hemophiliacs. <span><span class="ref-journal">Viral Immunol. </span>2005;<span class="ref-vol">18</span>:500\xe2\x80\x93505. doi: 10.1089/vim.2005.18.500.</span> [<a href="/pubmed/16212528" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1089%2Fvim.2005.18.500" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Viral+Immunol&amp;title=HLA-B+polymorphism+in+Japanese+HIV-1-infected+long-term+surviving+hemophiliacs&amp;author=M+Munkanta&amp;author=H+Terunuma&amp;author=M+Takahashi&amp;author=H+Hanabusa&amp;author=T+Miura&amp;volume=18&amp;publication_year=2005&amp;pages=500-505&amp;pmid=16212528&amp;doi=10.1089/vim.2005.18.500&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR27">27. <span class="element-citation">Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, Hallahan CW, Selig SM, Schwartz D, Sullivan J, Connors M. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2000;<span class="ref-vol">97</span>:2709\xe2\x80\x932714. doi: 10.1073/pnas.050567397.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC15994/">PMC free article</a>]</span> [<a href="/pubmed/10694578" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.050567397" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=HLA+B*5701+is+highly+associated+with+restriction+of+virus+replication+in+a+subgroup+of+HIV-infected+long+term+nonprogressors&amp;author=SA+Migueles&amp;author=MS+Sabbaghian&amp;author=WL+Shupert&amp;author=MP+Bettinotti&amp;author=FM+Marincola&amp;volume=97&amp;publication_year=2000&amp;pages=2709-2714&amp;pmid=10694578&amp;doi=10.1073/pnas.050567397&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR28">28. <span class="element-citation">den Uyl D, van der Horst-Bruinsma IE, van Agtmael M. Progression of HIV to AIDS: a protective role for HLA-B27? <span><span class="ref-journal">AIDS Rev. </span>2004;<span class="ref-vol">6</span>:89\xe2\x80\x9396.</span> [<a href="/pubmed/15332431" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AIDS+Rev&amp;title=Progression+of+HIV+to+AIDS:+a+protective+role+for+HLA-B27?&amp;author=D+den+Uyl&amp;author=IE+van+der+Horst-Bruinsma&amp;author=M+van+Agtmael&amp;volume=6&amp;publication_year=2004&amp;pages=89-96&amp;pmid=15332431&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR29">29. <span class="element-citation">Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, Young M, Greenblatt R, Sacks H, Feldman J. The Women\'s Interagency HIV Study. WIHS Collaborative Study Group. <span><span class="ref-journal">Epidemiology. </span>1998;<span class="ref-vol">9</span>:117\xe2\x80\x93125. doi: 10.1097/00001648-199803000-00004.</span> [<a href="/pubmed/9504278" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1097%2F00001648-199803000-00004" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Epidemiology&amp;title=The+Women\'s+Interagency+HIV+Study.+WIHS+Collaborative+Study+Group&amp;author=SE+Barkan&amp;author=SL+Melnick&amp;author=S+Preston-Martin&amp;author=K+Weber&amp;author=LA+Kalish&amp;volume=9&amp;publication_year=1998&amp;pages=117-125&amp;pmid=9504278&amp;doi=10.1097/00001648-199803000-00004&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR30">30. <span class="element-citation">Muchardt C, Seeler JS, Nirula A, Gong S, Gaynor R. Transcription factor AP-2 activates gene expression of HTLV-I. <span><span class="ref-journal">Embo J. </span>1992;<span class="ref-vol">11</span>:2573\xe2\x80\x932581.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC556732/">PMC free article</a>]</span> [<a href="/pubmed/1628621" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Embo+J&amp;title=Transcription+factor+AP-2+activates+gene+expression+of+HTLV-I&amp;author=C+Muchardt&amp;author=JS+Seeler&amp;author=A+Nirula&amp;author=S+Gong&amp;author=R+Gaynor&amp;volume=11&amp;publication_year=1992&amp;pages=2573-2581&amp;pmid=1628621&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR31">31. <span class="element-citation">Seeler JS, Muchardt C, Suessle A, Gaynor RB. Transcription factor PRDII-BF1 activates human immunodeficiency virus type 1 gene expression. <span><span class="ref-journal">J Virol. </span>1994;<span class="ref-vol">68</span>:1002\xe2\x80\x931009.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC236538/">PMC free article</a>]</span> [<a href="/pubmed/8289330" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Transcription+factor+PRDII-BF1+activates+human+immunodeficiency+virus+type+1+gene+expression&amp;author=JS+Seeler&amp;author=C+Muchardt&amp;author=A+Suessle&amp;author=RB+Gaynor&amp;volume=68&amp;publication_year=1994&amp;pages=1002-1009&amp;pmid=8289330&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR32">32. <span class="element-citation">Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, Aunis D, Rohr O. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. <span><span class="ref-journal">Embo J. </span>2007;<span class="ref-vol">26</span>:412\xe2\x80\x93423. doi: 10.1038/sj.emboj.7601516.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1783449/">PMC free article</a>]</span> [<a href="/pubmed/17245431" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2Fsj.emboj.7601516" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Embo+J&amp;title=Recruitment+of+chromatin-modifying+enzymes+by+CTIP2+promotes+HIV-1+transcriptional+silencing&amp;author=C+Marban&amp;author=S+Suzanne&amp;author=F+Dequiedt&amp;author=S+de+Walque&amp;author=L+Redel&amp;volume=26&amp;publication_year=2007&amp;pages=412-423&amp;pmid=17245431&amp;doi=10.1038/sj.emboj.7601516&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR33">33. <span class="element-citation">Pumfery A, Deng L, Maddukuri A, de la Fuente C, Li H, Wade JD, Lambert P, Kumar A, Kashanchi F. Chromatin remodeling and modification during HIV-1 Tat-activated transcription. <span><span class="ref-journal">Curr HIV Res. </span>2003;<span class="ref-vol">1</span>:343\xe2\x80\x93362. doi: 10.2174/1570162033485186.</span> [<a href="/pubmed/15046258" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.2174%2F1570162033485186" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+HIV+Res&amp;title=Chromatin+remodeling+and+modification+during+HIV-1+Tat-activated+transcription&amp;author=A+Pumfery&amp;author=L+Deng&amp;author=A+Maddukuri&amp;author=C+de+la+Fuente&amp;author=H+Li&amp;volume=1&amp;publication_year=2003&amp;pages=343-362&amp;pmid=15046258&amp;doi=10.2174/1570162033485186&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR34">34. <span class="element-citation">Shoeman RL, Sachse C, Honer B, Mothes E, Kaufmann M, Traub P. Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodeficiency virus type 1 protease. Actin, desmin, myosin, and tropomyosin. <span><span class="ref-journal">Am J Pathol. </span>1993;<span class="ref-vol">142</span>:221\xe2\x80\x93230.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1886840/">PMC free article</a>]</span> [<a href="/pubmed/8424456" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Pathol&amp;title=Cleavage+of+human+and+mouse+cytoskeletal+and+sarcomeric+proteins+by+human+immunodeficiency+virus+type+1+protease.+Actin,+desmin,+myosin,+and+tropomyosin&amp;author=RL+Shoeman&amp;author=C+Sachse&amp;author=B+Honer&amp;author=E+Mothes&amp;author=M+Kaufmann&amp;volume=142&amp;publication_year=1993&amp;pages=221-230&amp;pmid=8424456&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR35">35. <span class="element-citation">Parada NA, Cruikshank WW, Danis HL, Ryan TC, Center DM. IL-16-and other CD4 ligand-induced migration is dependent upon protein kinase C. <span><span class="ref-journal">Cell Immunol. </span>1996;<span class="ref-vol">168</span>:100\xe2\x80\x93106. doi: 10.1006/cimm.1996.0054.</span> [<a href="/pubmed/8599832" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1006%2Fcimm.1996.0054" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Immunol&amp;title=IL-16-and+other+CD4+ligand-induced+migration+is+dependent+upon+protein+kinase+C&amp;author=NA+Parada&amp;author=WW+Cruikshank&amp;author=HL+Danis&amp;author=TC+Ryan&amp;author=DM+Center&amp;volume=168&amp;publication_year=1996&amp;pages=100-106&amp;pmid=8599832&amp;doi=10.1006/cimm.1996.0054&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR36">36. <span class="element-citation">Leghmari K, Bennasser Y, Bahraoui E. HIV-1 Tat protein induces IL-10 production in monocytes by classical and alternative NF-kappaB pathways. <span><span class="ref-journal">Eur J Cell Biol. </span>2008;<span class="ref-vol">87</span>:947\xe2\x80\x93962. doi: 10.1016/j.ejcb.2008.06.005.</span> [<a href="/pubmed/18760861" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.ejcb.2008.06.005" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Cell+Biol&amp;title=HIV-1+Tat+protein+induces+IL-10+production+in+monocytes+by+classical+and+alternative+NF-kappaB+pathways&amp;author=K+Leghmari&amp;author=Y+Bennasser&amp;author=E+Bahraoui&amp;volume=87&amp;publication_year=2008&amp;pages=947-962&amp;pmid=18760861&amp;doi=10.1016/j.ejcb.2008.06.005&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR37">37. <span class="element-citation">Contreras X, Bennasser Y, Chazal N, Moreau M, Leclerc C, Tkaczuk J, Bahraoui E. Human immunodeficiency virus type 1 Tat protein induces an intracellular calcium increase in human monocytes that requires DHP receptors: involvement in TNF-alpha production. <span><span class="ref-journal">Virology. </span>2005;<span class="ref-vol">332</span>:316\xe2\x80\x93328. doi: 10.1016/j.virol.2004.11.032.</span> [<a href="/pubmed/15661163" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.virol.2004.11.032" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virology&amp;title=Human+immunodeficiency+virus+type+1+Tat+protein+induces+an+intracellular+calcium+increase+in+human+monocytes+that+requires+DHP+receptors:+involvement+in+TNF-alpha+production&amp;author=X+Contreras&amp;author=Y+Bennasser&amp;author=N+Chazal&amp;author=M+Moreau&amp;author=C+Leclerc&amp;volume=332&amp;publication_year=2005&amp;pages=316-328&amp;pmid=15661163&amp;doi=10.1016/j.virol.2004.11.032&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR38">38. <span class="element-citation">Bennasser Y, Badou A, Tkaczuk J, Bahraoui E. Signaling pathways triggered by HIV-1 Tat in human monocytes to induce TNF-alpha. <span><span class="ref-journal">Virology. </span>2002;<span class="ref-vol">303</span>:174\xe2\x80\x93180. doi: 10.1006/viro.2002.1676.</span> [<a href="/pubmed/12482669" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1006%2Fviro.2002.1676" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virology&amp;title=Signaling+pathways+triggered+by+HIV-1+Tat+in+human+monocytes+to+induce+TNF-alpha&amp;author=Y+Bennasser&amp;author=A+Badou&amp;author=J+Tkaczuk&amp;author=E+Bahraoui&amp;volume=303&amp;publication_year=2002&amp;pages=174-180&amp;pmid=12482669&amp;doi=10.1006/viro.2002.1676&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR39">39. <span class="element-citation">Bennasser Y, Bahraoui E. HIV-1 Tat protein induces interleukin-10 in human peripheral blood monocytes: involvement of protein kinase C-betaII and-delta. <span><span class="ref-journal">Faseb J. </span>2002;<span class="ref-vol">16</span>:546\xe2\x80\x93554. doi: 10.1096/fj.01-0775com.</span> [<a href="/pubmed/11919157" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1096%2Ffj.01-0775com" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Faseb+J&amp;title=HIV-1+Tat+protein+induces+interleukin-10+in+human+peripheral+blood+monocytes:+involvement+of+protein+kinase+C-betaII+and-delta&amp;author=Y+Bennasser&amp;author=E+Bahraoui&amp;volume=16&amp;publication_year=2002&amp;pages=546-554&amp;pmid=11919157&amp;doi=10.1096/fj.01-0775com&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR40">40. <span class="element-citation">Jakobovits A, Rosenthal A, Capon DJ. Trans-activation of HIV-1 LTR-directed gene expression by tat requires protein kinase C. <span><span class="ref-journal">Embo J. </span>1990;<span class="ref-vol">9</span>:1165\xe2\x80\x931170.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC551792/">PMC free article</a>]</span> [<a href="/pubmed/2182321" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Embo+J&amp;title=Trans-activation+of+HIV-1+LTR-directed+gene+expression+by+tat+requires+protein+kinase+C&amp;author=A+Jakobovits&amp;author=A+Rosenthal&amp;author=DJ+Capon&amp;volume=9&amp;publication_year=1990&amp;pages=1165-1170&amp;pmid=2182321&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR41">41. <span class="element-citation">Holmes AM. <em>In vitro</em> phosphorylation of human immunodeficiency virus type 1 Tat protein by protein kinase C: evidence for the phosphorylation of amino acid residue serine-46. <span><span class="ref-journal">Arch Biochem Biophys. </span>1996;<span class="ref-vol">335</span>:8\xe2\x80\x9312. doi: 10.1006/abbi.1996.0476.</span> [<a href="/pubmed/8914829" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1006%2Fabbi.1996.0476" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Arch+Biochem+Biophys&amp;title=In+vitro+phosphorylation+of+human+immunodeficiency+virus+type+1+Tat+protein+by+protein+kinase+C:+evidence+for+the+phosphorylation+of+amino+acid+residue+serine-46&amp;author=AM+Holmes&amp;volume=335&amp;publication_year=1996&amp;pages=8-12&amp;pmid=8914829&amp;doi=10.1006/abbi.1996.0476&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR42">42. <span class="element-citation">Schecter AD, Berman AB, Yi L, Mosoian A, McManus CM, Berman JW, Klotman ME, Taubman MB. HIV envelope gp120 activates human arterial smooth muscle cells. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2001;<span class="ref-vol">98</span>:10142\xe2\x80\x9310147. doi: 10.1073/pnas.181328798.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC56929/">PMC free article</a>]</span> [<a href="/pubmed/11504923" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.181328798" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+USA&amp;title=HIV+envelope+gp120+activates+human+arterial+smooth+muscle+cells&amp;author=AD+Schecter&amp;author=AB+Berman&amp;author=L+Yi&amp;author=A+Mosoian&amp;author=CM+McManus&amp;volume=98&amp;publication_year=2001&amp;pages=10142-10147&amp;pmid=11504923&amp;doi=10.1073/pnas.181328798&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR43">43. <span class="element-citation">Huang MB, Bond VC. Involvement of protein kinase C in HIV-1 gp120-induced apoptosis in primary endothelium. <span><span class="ref-journal">J Acquir Immune Defic Syndr. </span>2000;<span class="ref-vol">25</span>:375\xe2\x80\x93389. doi: 10.1097/00126334-200012150-00001.</span> [<a href="/pubmed/11141237" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1097%2F00126334-200012150-00001" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Acquir+Immune+Defic+Syndr&amp;title=Involvement+of+protein+kinase+C+in+HIV-1+gp120-induced+apoptosis+in+primary+endothelium&amp;author=MB+Huang&amp;author=VC+Bond&amp;volume=25&amp;publication_year=2000&amp;pages=375-389&amp;pmid=11141237&amp;doi=10.1097/00126334-200012150-00001&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR44">44. <span class="element-citation">Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. <span><span class="ref-journal">Trends Biochem Sci. </span>2005;<span class="ref-vol">30</span>:630\xe2\x80\x93641. doi: 10.1016/j.tibs.2005.09.005.</span> [<a href="/pubmed/16236519" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.tibs.2005.09.005" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Trends+Biochem+Sci&amp;title=Mammalian+cyclin-dependent+kinases&amp;author=M+Malumbres&amp;author=M+Barbacid&amp;volume=30&amp;publication_year=2005&amp;pages=630-641&amp;pmid=16236519&amp;doi=10.1016/j.tibs.2005.09.005&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR45">45. <span class="element-citation">Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. <span><span class="ref-journal">Biochim Biophys Acta. </span>2002;<span class="ref-vol">1602</span>:73\xe2\x80\x9387.</span> [<a href="/pubmed/11960696" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochim+Biophys+Acta&amp;title=Cyclin+D-dependent+kinases,+INK4+inhibitors+and+cancer&amp;author=S+Ortega&amp;author=M+Malumbres&amp;author=M+Barbacid&amp;volume=1602&amp;publication_year=2002&amp;pages=73-87&amp;pmid=11960696&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR46">46. <span class="element-citation">Guo Z, Stiller JW. Comparative genomics of cyclin-dependent kinases suggest co-evolution of the RNAP II C-terminal domain and CTD-directed CDKs. <span><span class="ref-journal">BMC Genomics. </span>2004;<span class="ref-vol">5</span>:69. doi: 10.1186/1471-2164-5-69.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC521075/">PMC free article</a>]</span> [<a href="/pubmed/15380029" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1186%2F1471-2164-5-69" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=BMC+Genomics&amp;title=Comparative+genomics+of+cyclin-dependent+kinases+suggest+co-evolution+of+the+RNAP+II+C-terminal+domain+and+CTD-directed+CDKs&amp;author=Z+Guo&amp;author=JW+Stiller&amp;volume=5&amp;publication_year=2004&amp;pages=69&amp;pmid=15380029&amp;doi=10.1186/1471-2164-5-69&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR47">47. <span class="element-citation">Nielsen AL, Oulad-Abdelghani M, Ortiz JA, Remboutsika E, Chambon P, Losson R. Heterochromatin formation in mammalian cells: interaction between histones and HP1 proteins. <span><span class="ref-journal">Mol Cell. </span>2001;<span class="ref-vol">7</span>:729\xe2\x80\x93739. doi: 10.1016/S1097-2765(01)00218-0.</span> [<a href="/pubmed/11336697" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS1097-2765(01)00218-0" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cell&amp;title=Heterochromatin+formation+in+mammalian+cells:+interaction+between+histones+and+HP1+proteins&amp;author=AL+Nielsen&amp;author=M+Oulad-Abdelghani&amp;author=JA+Ortiz&amp;author=E+Remboutsika&amp;author=P+Chambon&amp;volume=7&amp;publication_year=2001&amp;pages=729-739&amp;pmid=11336697&amp;doi=10.1016/S1097-2765(01)00218-0&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR48">48. <span class="element-citation">Smallwood A, Esteve PO, Pradhan S, Carey M. Functional cooperation between HP1 and DNMT1 mediates gene silencing. <span><span class="ref-journal">Genes Dev. </span>2007;<span class="ref-vol">21</span>:1169\xe2\x80\x931178. doi: 10.1101/gad.1536807.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1865489/">PMC free article</a>]</span> [<a href="/pubmed/17470536" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1101%2Fgad.1536807" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Genes+Dev&amp;title=Functional+cooperation+between+HP1+and+DNMT1+mediates+gene+silencing&amp;author=A+Smallwood&amp;author=PO+Esteve&amp;author=S+Pradhan&amp;author=M+Carey&amp;volume=21&amp;publication_year=2007&amp;pages=1169-1178&amp;pmid=17470536&amp;doi=10.1101/gad.1536807&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR49">49. <span class="element-citation">Loyola A, Tagami H, Bonaldi T, Roche D, Quivy JP, Imhof A, Nakatani Y, Dent SY, Almouzni G. The HP1alpha-CAF1-SetDB1-containing complex provides H3K9me1 for Suv39-mediated K9me3 in pericentric heterochromatin. <span><span class="ref-journal">EMBO Rep. </span>2009;<span class="ref-vol">10</span>:769\xe2\x80\x93775. doi: 10.1038/embor.2009.90.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2727428/">PMC free article</a>]</span> [<a href="/pubmed/19498464" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2Fembor.2009.90" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=EMBO+Rep&amp;title=The+HP1alpha-CAF1-SetDB1-containing+complex+provides+H3K9me1+for+Suv39-mediated+K9me3+in+pericentric+heterochromatin&amp;author=A+Loyola&amp;author=H+Tagami&amp;author=T+Bonaldi&amp;author=D+Roche&amp;author=JP+Quivy&amp;volume=10&amp;publication_year=2009&amp;pages=769-775&amp;pmid=19498464&amp;doi=10.1038/embor.2009.90&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR50">50. <span class="element-citation">du Chene I, Basyuk E, Lin YL, Triboulet R, Knezevich A, Chable-Bessia C, Mettling C, Baillat V, Reynes J, Corbeau P, Bertrand E, Marcello A, Emiliani S, Kiernan R, Benkirane M. Suv39H1 and HP1gamma are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. <span><span class="ref-journal">Embo J. </span>2007;<span class="ref-vol">26</span>:424\xe2\x80\x93435. doi: 10.1038/sj.emboj.7601517.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1783455/">PMC free article</a>]</span> [<a href="/pubmed/17245432" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2Fsj.emboj.7601517" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Embo+J&amp;title=Suv39H1+and+HP1gamma+are+responsible+for+chromatin-mediated+HIV-1+transcriptional+silencing+and+post-integration+latency&amp;author=I+du+Chene&amp;author=E+Basyuk&amp;author=YL+Lin&amp;author=R+Triboulet&amp;author=A+Knezevich&amp;volume=26&amp;publication_year=2007&amp;pages=424-435&amp;pmid=17245432&amp;doi=10.1038/sj.emboj.7601517&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR51">51. <span class="element-citation">Broude EV, Swift ME, Vivo C, Chang BD, Davis BM, Kalurupalle S, Blagosklonny MV, Roninson IB. p21(Waf1/Cip1/Sdi1) mediates retinoblastoma protein degradation. <span><span class="ref-journal">Oncogene. </span>2007;<span class="ref-vol">26</span>:6954\xe2\x80\x936958. doi: 10.1038/sj.onc.1210516.</span> [<a href="/pubmed/17486059" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2Fsj.onc.1210516" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=p21(Waf1/Cip1/Sdi1)+mediates+retinoblastoma+protein+degradation&amp;author=EV+Broude&amp;author=ME+Swift&amp;author=C+Vivo&amp;author=BD+Chang&amp;author=BM+Davis&amp;volume=26&amp;publication_year=2007&amp;pages=6954-6958&amp;pmid=17486059&amp;doi=10.1038/sj.onc.1210516&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR52">52. <span class="element-citation">Soni R, Muller L, Furet P, Schoepfer J, Stephan C, Zumstein-Mecker S, Fretz H, Chaudhuri B. Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. <span><span class="ref-journal">Biochem Biophys Res Commun. </span>2000;<span class="ref-vol">275</span>:877\xe2\x80\x93884. doi: 10.1006/bbrc.2000.3349.</span> [<a href="/pubmed/10973815" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1006%2Fbbrc.2000.3349" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+Biophys+Res+Commun&amp;title=Inhibition+of+cyclin-dependent+kinase+4+(Cdk4)+by+fascaplysin,+a+marine+natural+product&amp;author=R+Soni&amp;author=L+Muller&amp;author=P+Furet&amp;author=J+Schoepfer&amp;author=C+Stephan&amp;volume=275&amp;publication_year=2000&amp;pages=877-884&amp;pmid=10973815&amp;doi=10.1006/bbrc.2000.3349&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR53">53. <span class="element-citation">Mahale S, Aubry C, James Wilson A, Jenkins PR, Marechal JD, Sutcliffe MJ, Chaudhuri B. CA224, a non-planar analogue of fascaplysin, inhibits Cdk4 but not Cdk2 and arrests cells at G0/G1 inhibiting pRB phosphorylation. <span><span class="ref-journal">Bioorg Med Chem Lett. </span>2006;<span class="ref-vol">16</span>:4272\xe2\x80\x934278. doi: 10.1016/j.bmcl.2006.05.065.</span> [<a href="/pubmed/16750360" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.bmcl.2006.05.065" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg+Med+Chem+Lett&amp;title=CA224,+a+non-planar+analogue+of+fascaplysin,+inhibits+Cdk4+but+not+Cdk2+and+arrests+cells+at+G0/G1+inhibiting+pRB+phosphorylation&amp;author=S+Mahale&amp;author=C+Aubry&amp;author=A+James+Wilson&amp;author=PR+Jenkins&amp;author=JD+Marechal&amp;volume=16&amp;publication_year=2006&amp;pages=4272-4278&amp;pmid=16750360&amp;doi=10.1016/j.bmcl.2006.05.065&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR54">54. <span class="element-citation">Kubo A, Kaye FJ. Searching for selective cyclin-dependent kinase inhibitors to target the retinoblastoma/p16 cancer gene pathway. <span><span class="ref-journal">J Natl Cancer Inst. </span>2001;<span class="ref-vol">93</span>:415\xe2\x80\x93417. doi: 10.1093/jnci/93.6.415.</span> [<a href="/pubmed/11259459" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1093%2Fjnci%2F93.6.415" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Natl+Cancer+Inst&amp;title=Searching+for+selective+cyclin-dependent+kinase+inhibitors+to+target+the+retinoblastoma/p16+cancer+gene+pathway&amp;author=A+Kubo&amp;author=FJ+Kaye&amp;volume=93&amp;publication_year=2001&amp;pages=415-417&amp;pmid=11259459&amp;doi=10.1093/jnci/93.6.415&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR55">55. <span class="element-citation">Ammosova T, Berro R, Jerebtsova M, Jackson A, Charles S, Klase Z, Southerland W, Gordeuk VR, Kashanchi F, Nekhai S. Phosphorylation of HIV-1 Tat by CDK2 in HIV-1 transcription. <span><span class="ref-journal">Retrovirology. </span>2006;<span class="ref-vol">3</span>:78. doi: 10.1186/1742-4690-3-78.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1636661/">PMC free article</a>]</span> [<a href="/pubmed/17083724" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1186%2F1742-4690-3-78" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Retrovirology&amp;title=Phosphorylation+of+HIV-1+Tat+by+CDK2+in+HIV-1+transcription&amp;author=T+Ammosova&amp;author=R+Berro&amp;author=M+Jerebtsova&amp;author=A+Jackson&amp;author=S+Charles&amp;volume=3&amp;publication_year=2006&amp;pages=78&amp;pmid=17083724&amp;doi=10.1186/1742-4690-3-78&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR56">56. <span class="element-citation">Deng L, Ammosova T, Pumfery A, Kashanchi F, Nekhai S. HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. <span><span class="ref-journal">J Biol Chem. </span>2002;<span class="ref-vol">277</span>:33922\xe2\x80\x9333929. doi: 10.1074/jbc.M111349200.</span> [<a href="/pubmed/12114499" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1074%2Fjbc.M111349200" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=HIV-1+Tat+interaction+with+RNA+polymerase+II+C-terminal+domain+(CTD)+and+a+dynamic+association+with+CDK2+induce+CTD+phosphorylation+and+transcription+from+HIV-1+promoter&amp;author=L+Deng&amp;author=T+Ammosova&amp;author=A+Pumfery&amp;author=F+Kashanchi&amp;author=S+Nekhai&amp;volume=277&amp;publication_year=2002&amp;pages=33922-33929&amp;pmid=12114499&amp;doi=10.1074/jbc.M111349200&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR57">57. <span class="element-citation">Nekhai S, Zhou M, Fernandez A, Lane WS, Lamb NJ, Brady J, Kumar A. HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription. <span><span class="ref-journal">Biochem J. </span>2002;<span class="ref-vol">364</span>:649\xe2\x80\x93657. doi: 10.1042/bj20011191.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1222613/">PMC free article</a>]</span> [<a href="/pubmed/12049628" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1042%2Fbj20011191" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+J&amp;title=HIV-1+Tat-associated+RNA+polymerase+C-terminal+domain+kinase,+CDK2,+phosphorylates+CDK7+and+stimulates+Tat-mediated+transcription&amp;author=S+Nekhai&amp;author=M+Zhou&amp;author=A+Fernandez&amp;author=WS+Lane&amp;author=NJ+Lamb&amp;volume=364&amp;publication_year=2002&amp;pages=649-657&amp;pmid=12049628&amp;doi=10.1042/bj20011191&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR58">58. <span class="element-citation">Coley W, Kehn-Hall K, Van Duyne R, Kashanchi F. Novel HIV-1 therapeutics through targeting altered host cell pathways. <span><span class="ref-journal">Expert Opin Biol Ther. </span>2009;<span class="ref-vol">9</span>:1369\xe2\x80\x931382. doi: 10.1517/14712590903257781.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2785118/">PMC free article</a>]</span> [<a href="/pubmed/19732026" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1517%2F14712590903257781" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Opin+Biol+Ther&amp;title=Novel+HIV-1+therapeutics+through+targeting+altered+host+cell+pathways&amp;author=W+Coley&amp;author=K+Kehn-Hall&amp;author=R+Van+Duyne&amp;author=F+Kashanchi&amp;volume=9&amp;publication_year=2009&amp;pages=1369-1382&amp;pmid=19732026&amp;doi=10.1517/14712590903257781&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR59">59. <span class="element-citation">Raucher D, Moktan S, Massodi I, Bidwell GL. Therapeutic peptides for cancer therapy. Part II - cell cycle inhibitory peptides and apoptosis-inducing peptides. <span><span class="ref-journal">Expert Opin Drug Deliv. </span>2009;<span class="ref-vol">6</span>:1049\xe2\x80\x931064. doi: 10.1517/17425240903158909.</span> [<a href="/pubmed/19743895" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1517%2F17425240903158909" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Expert+Opin+Drug+Deliv&amp;title=Therapeutic+peptides+for+cancer+therapy.+Part+II+-+cell+cycle+inhibitory+peptides+and+apoptosis-inducing+peptides&amp;author=D+Raucher&amp;author=S+Moktan&amp;author=I+Massodi&amp;author=GL+Bidwell&amp;volume=6&amp;publication_year=2009&amp;pages=1049-1064&amp;pmid=19743895&amp;doi=10.1517/17425240903158909&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR60">60. <span class="element-citation">Fahraeus R, Paramio JM, Ball KL, Lain S, Lane DP. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A. <span><span class="ref-journal">Curr Biol. </span>1996;<span class="ref-vol">6</span>:84\xe2\x80\x9391. doi: 10.1016/S0960-9822(02)00425-6.</span> [<a href="/pubmed/8805225" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0960-9822(02)00425-6" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Curr+Biol&amp;title=Inhibition+of+pRb+phosphorylation+and+cell-cycle+progression+by+a+20-residue+peptide+derived+from+p16CDKN2/INK4A&amp;author=R+Fahraeus&amp;author=JM+Paramio&amp;author=KL+Ball&amp;author=S+Lain&amp;author=DP+Lane&amp;volume=6&amp;publication_year=1996&amp;pages=84-91&amp;pmid=8805225&amp;doi=10.1016/S0960-9822(02)00425-6&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR61">61. <span class="element-citation">Fahraeus R, Lane DP. The p16(INK4a) tumour suppressor protein inhibits alphavbeta3 integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alphavbeta3 to focal contacts. <span><span class="ref-journal">Embo J. </span>1999;<span class="ref-vol">18</span>:2106\xe2\x80\x932118. doi: 10.1093/emboj/18.8.2106.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1171295/">PMC free article</a>]</span> [<a href="/pubmed/10205165" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1093%2Femboj%2F18.8.2106" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Embo+J&amp;title=The+p16(INK4a)+tumour+suppressor+protein+inhibits+alphavbeta3+integrin-mediated+cell+spreading+on+vitronectin+by+blocking+PKC-dependent+localization+of+alphavbeta3+to+focal+contacts&amp;author=R+Fahraeus&amp;author=DP+Lane&amp;volume=18&amp;publication_year=1999&amp;pages=2106-2118&amp;pmid=10205165&amp;doi=10.1093/emboj/18.8.2106&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR62">62. <span class="element-citation">Kondo E, Seto M, Yoshikawa K, Yoshino T. Highly efficient delivery of p16 antitumor peptide into aggressive leukemia/lymphoma cells using a novel transporter system. <span><span class="ref-journal">Mol Cancer Ther. </span>2004;<span class="ref-vol">3</span>:1623\xe2\x80\x931630.</span> [<a href="/pubmed/15634656" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer+Ther&amp;title=Highly+efficient+delivery+of+p16+antitumor+peptide+into+aggressive+leukemia/lymphoma+cells+using+a+novel+transporter+system&amp;author=E+Kondo&amp;author=M+Seto&amp;author=K+Yoshikawa&amp;author=T+Yoshino&amp;volume=3&amp;publication_year=2004&amp;pages=1623-1630&amp;pmid=15634656&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2908552&amp;issue-id=354895&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2908552/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2908552/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2908552/pdf/12981_2010_Article_150.pdf">PDF (2.5M)</a></li> | <li><a href="#" data-citationid="PMC2908552" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2908552%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2908552%2F&amp;text=The%20identification%20of%20unique%20serum%20proteins%20of%20HIV-1%20latently%20infected%20long-term%20non-progressor%20patients"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2908552%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="20604950" data-aiid="7100323" data-aid="2908552" data-iid="354895" data-domainid="3814" data-domain="phenaturepg" data-accid="PMC2908552" data-md5="919fdedc15421f74b46c36cf51183f29"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T20:44:20-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc102&amp;ncbi_phid=8A1BDA23E9A475410000000003760376&amp;ncbi_session=8A1BDA23E9A4D631_0886SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2908552%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=phenaturepg&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2908552/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1BDA23E9A4D631_0886SID /projects/PMC/PMCViewer@4.46 ptpmc102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'